Categories
Report

(NYSE: MAIA) Profile

______________________

MAIA BOASTS A ROBUST CLINICAL PIPELINE IN MULTIPLE HARD-TO-TREAT CANCER INDICATIONS

FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA.

   -THIS IS THE THIRD ORPHAN DRUG DESIGNATION GRANTED TO THIO

MAIA Just Made Another 52 Week High Earlier in This Session

READ THE INVESTOR PRESENTATION HERE

_______________________________________________________________________________________________________________

Hello Everyone,

We have a new NYSE profile for Today’s session.

This is a company that we have profiled in the past at much lower levels.

Pull up MAIA and start your research on it immediately.

MAIA Just made another 52 week high today.

This one could be on the verge of a breakout here as it enters mid-$4 territory.

MAIA has been on a Bull Run since before the New Year and with a strong partnership with Regeneron on the books there is no telling what the limit on MAIA could be.

• Clinical supply agreement: Regeneron provides Libtayo® for THIO-101

• Equivalent to $32M non-dilutive participation (largest financing move to date)

• Potentially expand existing relationship and target new companies

‍

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a first-in-class cancer telomere targeting agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) patients with telomerase-positive cancer cells.

THIO is a Unique Direct Telomere Targeting Agent
• Potential to be used in combination with other anticancer and immune therapies
• Dual, novel mechanism of action: telomere targeting + immunogenic
• FDA awarded THIO 2 Orphan Drug Designations: HCC and SCLC!
• Excellent efficacy: achieved complete and durable responses in HCC in vivo models (peer-reviewed published study)

Strong and Growing IP Portfolio

• Potential for receiving NCE marketing exclusivity; 5 patents issued, 12 patent applications pending Next Generation Potential Telomere Targeting Therapeutics
• 84 new molecules engineered in last 12 months; Same mechanism of action as THIO
• MAIA-2021-020, MAIA-2022-012 and MAIA-2021-029 significantly more efficacious
• Follow THIO to commercial stage within 4-5 years

MAIA BIOTECHNOLOGY PROVIDES POSITIVE PHASE 2 CLINICAL UPDATES FOR LEAD ANTICANCER AGENT AND OUTLINES TARGETED MILESTONES FOR 2024

January 17, 2024 9:00am EST

  • Lead candidate THIO maintains unprecedented disease control rates in Phase 2 non-small cell lung cancer (NSCLC) clinical trial
  • Multiple clinical milestones ahead for THIO-101 Phase 2 trial
  • Company enters 2024 with robust clinical pipeline in multiple hard-to-treat cancer indications

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced new interim data for its ongoing THIO-101 Phase 2 trial in non-small cell lung cancer (NSCLC) and outlined key clinical milestones for 2024.

In the latest available data from THIO-101 (November 13, 2023), 60 patients had been dosed with THIO in sequential combination with Libtayo®. The patients received either 60mg, 180mg, or 360mg of THIO per dose, and 42 had at least one post baseline assessment completed. The observed disease control was well sustained compared to previous scans.

“We are entering 2024 with strong momentum and great excitement about our programs and pipeline,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “To date, preliminary Phase 2 data on THIO in NSCLC has demonstrated unprecedented rates of disease control and response — measures that vastly outperform the standard of care.”

“In addition to NSCLC, our pipeline of immuno-oncology therapies includes THIO orphan drug designations for multiple hard-to-treat cancers, and our research includes THIO-like second-generation telomere-targeting agents. The main objective for the second-generation program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity,” Dr. Vitoc continued.

“Multiple milestones are on target for 2024 as enrollment continues in THIO-101, including long-term efficacy as a major clinical inflection point.”

Key 2023 Achievements

Positive Preliminary Efficacy Data: Key findings from THIO-101 included:

  • 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatment.
  • DCR across all dose levels met pre-determined statistical requirements earlier than expected to proceed to next stage of the trial.

Third orphan drug designation (ODD) granted to THIO: MAIA’s portfolio of immuno-oncology therapies with ODDs now includes a third hard-to-treat cancer, glioblastoma, the most aggressive and most common type of brain cancer with only limited treatment options.

U.S. FDA Investigational New Drug (IND) Clearance: The FDA cleared U.S.-based evaluation for THIO as part of THIO-101. The trial drew a strong pace of enrollment in 2023 compared with previous NSCLC trials by other drug developers.

Dose Selection: A 180mg/cycle dose of THIO was selected for THIO-101 based on stronger efficacy compared to other doses. The selected dose showed unprecedented disease control and overall response rates for a NSCLC clinical trial.

Next Generation Telomere Targeting Agents: MAIA’s second-generation telomere-targeting program is engaged in research and development for new prodrugs derived from lipid-modified THIO molecules. Capable of acting through similar mechanisms of activity as THIO, the higher potency of these compounds at lower dose levels will be investigated further in 2024.

THIO is the only direct telomere targeting agent currently undergoing clinical development in the field of cancer drug discovery and treatment.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101, a Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of THIO administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. Treatment with cemiplimab (Libtayo®) followed by THIO has been generally well-tolerated to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA

  • Third orphan drug designation (ODD) granted to THIO by the FDA; drug also holds ODDs for hepatocellular carcinoma and small cell lung cancer
  • Benefits include 7 years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing
  • Expected glioblastoma market growth from $2.2 billion to $3.2 billion globally in the next three years

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to its lead asset THIO, a cancer telomere-targeting agent, for the treatment of glioblastoma. This is the third orphan drug designation granted to THIO, following the receipt of orphan drug designations for hepatocellular carcinoma (HCC) and small cell lung cancer (SCLC) in 2022.

“We are pleased to receive a third orphan drug designation for THIO, further highlighting FDA’s recognition of THIO’s potential in the treatment of multiple cancer indications, including rare ones such as glioblastoma,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “Each year, globally, more than 300,000 people are diagnosed with brain tumors, of which, 25,000 are in the United States. Glioblastoma represents the majority of these cases in the U.S., with 15,000 new patients diagnosed and more than 10,000 deaths yearly, making it an orphan indication. Given this prevalence there is significant room for growth in the $2.2 billion glioblastoma market, which is expected to reach $3.2 billion globally in the next three years.1 We consider this ODD an important milestone for our development strategy and for glioblastoma patients who could benefit from a potentially revolutionary therapy.”

“In the data presented to the FDA, THIO successfully penetrated the blood brain barrier (BBB) in syngeneic and humanized mouse models of telomerase-expressing brain cancers. Treatment with THIO resulted in potent anticancer activity and significant expansion of the animal lifespan for several difficult to treat cell lines and xenograft mouse models,” added Sergei Gryaznov, Ph.D., MAIA’s Chief Scientific Officer. “These results stem from THIO’s remarkable mechanism of action and its BBB penetrating property that allows for direct targeting of brain tumors in vivo and potentially in glioblastoma patients.”

“Glioblastoma is the most aggressive and most common type of cancer that originates in the brain. With very limited treatment options available, glioblastoma patients have exceptionally short survival durations, and only 7% remain alive five years after being diagnosed with the condition,”2 said Mihail Obrocea, MD, MAIA’s Chief Medical Officer. “We are optimistic about our telomere-targeting agent’s ability to provide clinical benefit in patients with glioblastoma, and we look forward to studying THIO for the treatment of this highly unmet medical indication in a future trial.”

Enrollment is ongoing in a Phase 2 trial of THIO, THIO-101, evaluating the drug candidate in patients with advanced non-small cell lung cancer (NSCLC). THIO is the only direct telomere targeting agent currently in clinical development.

About Orphan Drug Designation

The FDA’s Orphan Drug Act of 1983 was designed to incentivize the development of therapies that demonstrate promise for the treatment of rare (orphan) diseases or conditions. A disease is classified as “rare” if it affects fewer than 200,000 people total in the U.S., or if the cost of developing a drug and making it available in the U.S. for such diseases will exceed any potential profits from its sale due to the small target population size. The FDA’s ODD program provides multiple incentives to make orphan drug development more financially possible for companies to pursue, such as up to seven years of market exclusivity for the approved orphan drug, up to 20 years of 25% federal tax credit for expenses incurred in conducting clinical research within the U.S. and waiver of Prescription Drug User Fee Act (PDUFA) fees for orphan drugs, a value of approximately $2.9 million in 2021.

Significant Market Opportunity

  • Cancer is the most dominant of the age-related disease categories and has life altering impacts in the lives of patients and their close ones
  • The number oF people aged 80 years or older is expectedtotriplebetween 2020 and 2050 to reach 426 million
  • Approximately40%ofpeoplealivetodayareprojectedtobediagnosed with a cancer type in their lifetime, and 20% will die of it
  • NSCLC is the leading tumor type: Mortality 1.7M / Sales $32B (2022)
  • CRCissecond:Mortality1M/Sales$20B(2022)

Clinical Programs

THIO-101: Ph 2 trial THIO + LIBTAYO® (cemiplimab) – enrolling (35 patients dosed to date)

  • Go-to-market trial in second line NSCLC
  • Objectives: select most efficacious dose and expand into pivotal trial
  • Started in 2022 in Australia & Europe; to include US in 2023
  • Regeneron clinical supply agreement for Libtayo®
  • File for accelerated approval in 2025
  • Part A (Safety Lead-in) Complete: No dose-limiting toxicities (DLTs), No Serious Adverse Events (SAE) or Serious Unexpected Suspected Adverse Reactions (SUSAR); Safety profile substantially better than current Standard of Care (SoC)
  • Preliminary Survival: first 2 patients dosed in Part A continue to be alive, 12.2 and 11.5 months from treatment initiation; progression free after last dose, 10.2 and 8.5 months respectively, with no new treatment; in real-world clinical practice, observed survival in similar heavily pretreated patients is 3-4 months; weeks without therapy
  • Disease Control Rate: 82%; subjects with 1+ post-baseline response assessment (n=11, 06/23/23); DCR for SoC in third line: 25-35%
  • Part B (efficacy/dose selection) initiated THIO-102: Ph 2 trial THIO + CPIs
  • Go-to-market trial in late line of therapy in multiple tumor. types: Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC, 90% of primary type of liver cancers), and Solid Tumors of any type (ST)
  • 3 umbrellas in each: THIO + Libtayo (REGN); Keytruda (MRK); Tecentriq (Genentech/Roche)
  • Objectives: select most efficacious combination by tumor type and expand into pivotal trials (9+ possible market entry indications)
  • Start in 2023, to include US, Europe, Asia, etc.
  • File for accelerated approvals in 2026 and beyond THIO-103: Ph 2/3 trial of THIO + CPIs
  • First line NSCLC and SCLC
  • Expand to Breast, Prostate, Pancreatic, Ovarian, Gastric Cancer, etc.

THIO is a Unique Direct Telomere Targeting Agent
• Potential to be used in combination with other anticancer and immune therapies
• Dual, novel mechanism of action: telomere targeting + immunogenic
• FDA awarded THIO 2 Orphan Drug Designations: HCC and SCLC!
• Excellent efficacy: achieved complete and durable responses in HCC in vivo models (peer-reviewed published study)

COMPARABLE COMPANIES

MAIA BIOTECHNOLOGY ANNOUNCES STRONG EFFICACY OF THIO AS THIRD-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER PATIENTS

March 06, 2024 8:48am EST Download as PDF

  • Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, third-line non-small cell lung cancer (NSCLC)
  • ORR of 38% significantly exceeds standard of care ORR in NSCLC third-line in patients without a targetable mutation who progressed on checkpoint inhibitors and chemotherapy

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive efficacy data for third-line treatment in its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC).

As of January 8, 2024, overall response rate (ORR), characterized as partial or complete response to therapy, was 38% (3 out of 8 patients) in the efficacy evaluable population for combination THIO 180mg + cemiplimab in third-line treatment for NSCLC patients who failed treatment with immune checkpoint inhibitors in prior lines of therapy, with or without chemotherapy.

“As an impressive measure of efficacy, the strong response rate of 38% in third-line treatment supports our premise that THIO administration prior to cemiplimab can improve tumor responses to immunotherapy in advanced NSCLC patients resistant to CPIs and other standard treatments,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “Around 60-70% of NSCLC patients do not have a targetable mutation and cannot benefit from a biomarker-targeted therapy, making it the greatest unmet medical need population in lung cancer. In currently available treatments for these patients in third-line, response rates range around 6%.1 We are encouraged by the excellent efficacy findings in THIO-101 to date, adding impressive ORR to unprecented disease control rates (DCR), and further demonstrating the potential of our first-in-class treatment to redefine the standard of care for NSCLC patients.”

The efficacy evaluable population defined in the THIO-101 protocol considers all subjects who received at least one dose of THIO treatment and have at least one postbaseline tumor assessment (scans). Two third-line patients in the 180mg dose cohort did not have recorded scans at the data cutoff. Safety remained consistent with previous reports.

The Company recently announced early completion of enrollment in the THIO-101 trial. THIO-101 is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

NEWS

May 17, 2024 8:37am EDT

MAIA Biotechnology to Present at the BIO International Convention 2024

May 16, 2024 8:37am EDT

MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Apr 30, 2024 8:08am EDT

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

Apr 29, 2024 8:08am EDT

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement

Apr 23, 2024 8:51am EDT

MAIA Biotechnology Announces $1.00 Million Private Placement

Apr 05, 2024 8:01am EDT

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

Mar 28, 2024 3:00pm EDT

MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero

Mar 26, 2024 3:00pm EDT

MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement

Mar 26, 2024 8:01am EDT

MAIA Biotechnology Announces $1.33 Million Private Placement

Mar 22, 2024 3:00pm EDT

MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement

Mar 21, 2024 3:00pm EDT

MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

Mar 07, 2024 9:45am EST

MAIA Biotechnology to Participate in the 36th Annual ROTH Conference

Mar 06, 2024 11:04am EST

MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

Mar 06, 2024 8:48am EST

MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

Mar 05, 2024 8:45am EST

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders

Feb 27, 2024 10:30am EST

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Feb 22, 2024 10:30am EST

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Feb 07, 2024 8:01am EST

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Jan 24, 2024 7:15am EST

MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

Jan 17, 2024 9:00am EST

MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

Jan 05, 2024 8:00am EST

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

Dec 19, 2023 7:00am EST

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

‍

MANAGEMENT TEAM

team

VLAD VITOC, MD, MBA

CHIEF EXECUTIVE OFFICER AND CHAIRMAN

Dr. Vitoc is our Chairman of Board, Chief Executive Officer, and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer, prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.

team

JOSEPH F. MCGUIRE

CHIEF FINANCIAL OFFICER

Mr. McGuire is our Chief Financial Officer, and he brings over 30 years of experience to MAIA, having served as Chief Financial Officer for several privately held and publicly traded companies in the healt

team

SERGEI M. GRYAZNOV, PHD

CHIEF SCIENTIFIC OFFICER

Dr. Gryaznov is our Chief Scientific Officer. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules, and nucleic acid based therapeutic agents. Dr. Gryaznov is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO’s telomere targeting activity, our lead compound in development. Dr. Gryaznov obtained an M.S., with Honors, in Organic Chemistry and a Ph.D. in Chemistry of Natural Products from M.V. Lomonosov Moscow State University. Dr. Gryaznov also completed a post-doctoral fellowship program in Chemistry at Northwestern University in Evanston, IL.

team

MIHAIL OBROCEA, MD

CHIEF MEDICAL OFFICER

Mihail is a board-certified internist and hematologist/oncologist with over 25 years’ experience in drug development in both academia and pharmaceutical/biotechnology industry. His broad clinical drug development expertise in both hematology and oncology covers equally early and late-stage development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Mihail completed a residency program in internal medicine at Yale University followed by a fellowship program in hematology/oncology at Dartmouth with academic appointment as Instructor of Medicine in the division of Hematology & Oncology at Mary Hitchcock Medical Center and Geisel Medical School at Dartmouth.

He started his career in pharmaceutical industry at Pfizer Oncology leading the CD40 agonist and IGF-1R antibodies projects, which entered in early clinical trials. Subsequently he led the Medical Affairs Oncology group at MedImmune, Gaithersburg MD and later as VP, Clinical Development Oncology at MannKind Corp., Valencia, CA successfully brought into clinic two cancer vaccine programs. As a Global Project Lead for AbbVie Biotherapeutics in Redwood City, CA, he was responsible for the early clinical oncology monoclonal antibody programs and as Head, Medical Sciences at Pharmacyclics, Sunnyvale CA he took part in the commercial launch of ibrutinib (IMBRUVICA™) program in mantle cell lymphoma and chronic lymphocytic leukemia. As VP of Clinical and Medical Affairs at SFJ Pharmaceutical Group, a venture pharma company supported the medical and business operations of the Pfizer Oncology partnership on the Phase 3, pivotal trial which led to the FDA approval of Besponsa® (inotuzumab ozogamicin) in the R/R adult B-cell ALL.

Later as US Clinical Lead at Nanobiotix Corp, a biotechnology company based in Paris, France which develops nanotechnologies for use in radiation oncology, established the US clinical programs and was involved in the strategic business development, investor, and partner interaction. As a Program Lead at Juno Therapeutics Inc and later Celgene he had the US clinical oversight of 2 clinical trials including the registration Ph 3 trial in second line aggressive large B-cell lymphomas of BREYANZI® (lisocabtagene maralucel) an autologous CD19 targeted CAR T program approved in both US and EU in R/R large B-cell lymphoma. More recently, as Project and Clinical Lead at Atara Bio, a T-cell therapy company based in Thousand Oaks, CA he supported the pre-clinical and clinical development of the Atara’s allogeneic CAR T platform for both lymphoma and solid tumor indications.

Mihail published in oncology peer-reviewed literature and is co-author of a couple of books related to cancer vaccines and immunology as well as he holds several patents in the field of biotechnology.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND FIVE HUNDRED USD BY SICA MEDIA LLC FOR A ONE DAY MAIA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

INDP Profile

Indaptus Therapeutics

As of March 31, 2024, the Company had cash and cash equivalents of $9.7 million

Upcoming poster, titled, “Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors,” at the American Society of Clinical Oncology annual meeting on upcoming presentation in Chicago.

Reported preliminary positive results from second cohort of Phase 1 trial and initiated multi-dose cohort in March 2024.

Announced granting of key patent that helped to further expand intellectual property portfolio in January 2024.

Check Out the Investor Presentation HERE

Hello Everyone,

We have another company on our radar for Wednesdays session that has several catalysts that you are going to want to research.

Pull up INDP right away.

This one has under 6 million shares in the float.

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform.  The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts.  In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product. Indaptus’ Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Over the past 12 months we haven’t seen any insider selling. We did see one substantial Insider purchase over over 100K shares at 2.34, which are at moderately higher levels than it is currently sitting.

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Results Indicate Decoy Platform Broadly Boosts Immune System’s Ability to Fight Tumors Directly and Indirectly

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, was proud to unveil its poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday, April 10 th . The poster details mechanism of action data that demonstrates the Company’s Decoy platform successfully induces, matures or activates multiple immune cell types involved in anti-tumor responses.

The latest findings significantly enhance the Company’s understanding of its “Decoy” platform technology, which uses killed, non-pathogenic bacteria engineered to activate the immune system to attack tumors. The study highlights the platform’s effectiveness in engaging key innate and adaptive immune cells, including, natural killer cells, natural killer T cells, dendritic cells, CD4 + , and CD8 + T cells. In some settings, the platform also produced additive or synergistic activity in combination with IL-2, an approved cancer drug. Additionally, the data reveal that the Decoy platform may not only boost the immune system’s ability to recognize and kill tumor cells, but potentially also overcome a mechanism that suppresses the immune response. The results suggest that the Company’s Decoy bacteria can both directly and indirectly prime the immune system to more effectively fight cancer.

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors. This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20’s potential as a multifaceted immunotherapy.”

The Company recently initiated the multi-dose cohort of its Phase 1 clinical trial in solid tumors.

Jeffrey Meckler, Indaptus’ Chief Executive Officer, added, “We are encouraged by the promising results observed in our preclinical studies and our ongoing Phase 1 clinical trial. The recognition and validation from prestigious organizations such as the AACR, coupled with the support and insights we are receiving from medical experts, partners and investors at the conference, inspire us to continue advancing our technology and demonstrating its significant therapeutic potential for the treatment of solid tumors.”

The full poster can be accessed on the Indaptus Therapeutics website by clicking here .

https://x.com/indaptus/status/1767924964231921834?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1767924964231921834%7Ctwgr%5E4c14ecd2075f6769cc275fba1838280486225e16%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.insiderfinancial.com%2Fprofile%2Findp-profile33

SCIENCE & PIPELINE

Novel Insights. Novel Therapies.

Historically, we know that tumor regression has been observed in the presence of bacterial infection. We also know that bacteria contain immune system danger signals, called pathogen-associated molecular patterns (PAMPs), that collectively can activate all of the cellular components of our innate and adaptive immune pathways. PAMPs are recognized by receptors, such as Toll-like (TLR), NOD, STING and RIG-I, that are found on and involved in activation of many different innate and adaptive immune cells.

Our platform is based on the hypothesis that highly efficient anti-tumor immunotherapy will require safe activation of both innate and adaptive cellular immunity in both tumors and immune organs, and that this might be achieved with a multi-targeted package of bacterial PAMPs, in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. While current therapies are increasingly becoming more and more personalized and costly, we are advancing an approach designed to be widely accessible, with broad anti-tumor and anti-viral activity not dependent on the targeting of specific tumor or viral antigens.

Current Approaches

Current Approach

Current immunotherapies only cure a very small percentage of advanced cancer patients because they activate only one or a few innate or adaptive immune cell types.

The Indaptus Approach

Indaptus Approach

Goal: to safely and effectively activate both innate and adaptive cellular anti-tumor pathways by passively targeting both the tumor and  immune organs.

A Unique Approach

Previous research has shown that lipopolysaccharide (LPS), an endotoxin that binds to Toll-like receptor 4 (TLR4), is a key bacterial PAMP that activates the immune system. Activated TLR4 has been shown to play a role in dendritic cell activation and T-cell-mediated anti-tumor immune responses. Our novel insights have enabled us to create attenuated and killed, non-pathogenic gram-negative bacteria with unique levels of LPS – levels that have now been shown in pre-clinical studies to be sufficient to synergize with other PAMPs in the bacteria to safely prime and/or activate innate and adaptive immune pathways. We currently have a broad patent portfolio with 34 issued or granted patents that are based on the technology originally developed by our Founder and Chief Scientific Officer, Dr. Michael Newman, at Indaptus’ predecessor company, Decoy Biosystems.

Based on our successes to date, we are now building a pipeline of therapeutic candidates designed to be delivered intravenously, targeting cancers and infectious diseases with high unmet medical needs.

Results to Date

We are currently advancing our lead candidate, Decoy20, through Phase 1 clinical trial. To date, Decoy20 and/or related candidates have demonstrated broad anti-tumor and anti-viral activity in pre-clinical models, including high percentage complete and durable anti-tumor responses in combination with different classes of existing therapeutics.

  • In oncology, Decoy candidates have demonstrated the ability to eradicate established tumors in a murine model of hepatocellular carcinoma in combination with either a non-steroidal anti-inflammatory drug (NSAID) or an anti-PD-1 agent, and more efficiently with both. Tumor eradication has occurred with a wide therapeutic index and has led to induction of 100% immunological memory. In combination with low-dose chemotherapy, Decoy candidates have also produced highly efficient eradication of established tumors in a mouse model of non-Hodgkin’s Lymphoma (NHL), also with induction of immunological memory. Combination-mediated tumor eradication has also been observed with a human tumor xenograft NHL model with inclusion of a targeted antibody. Decoy candidates have also produced significant single agent activity in murine models of both metastatic pancreatic carcinoma and orthotopic, colorectal carcinoma.
  • In infectious disease, single agent Decoy therapeutics have produced significantly broader activity than standard of care treatment in a pre-clinical model of chronic Hepatitis B infection, as well as single agent activity against chronic HIV infection in a pre-clinical humanized mouse model.

Generation and/or activation of the cells required for innate and adaptive anti-tumor and anti-viral immune responses takes place, to a significant extent, outside of the tumor or sites of infection, including in the spleen. Our intravenous therapeutic candidates are expected to passively target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and HBV infection, the liver. As our therapeutic candidates are expected to be cleared very quickly by the liver and spleen, we anticipate a low risk of non-specific autoimmune side effects relative to other types of immunotherapies designed for continuous exposure.

We have initiated our Phase 1 clinical trial of Decoy20 in December 2022 and dosed our first patient in March 2023.

A graph showing dose timeline by quarter summarized by key milestones including single dose safety 2H 2023, multi-dose safety 2H 2024, and proof of concept late 2025 or early 2026.
Indaptus immunotherapy pipeline status chart

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, “We continue to make steady progress in our clinical development plans and are receiving regular validation for results reported to date, both through a presentation in April at the American Association for Cancer Research (AACR) annual meeting, and the acceptance of further data to be presented in a poster at the American Society of Clinical Oncology (ASCO) annual meeting, which is considered among the top annual oncology conferences. We are encouraged by the results we have reported, along with the early results we are seeing as we advance our trial, and believe they are indicative of the potential for Decoy20, and indeed our platform as a whole. We look forward to reporting more about our progress as it develops.”

Key recent highlights:

  • Presenting poster, titled, “Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors,” at the American Society of Clinical Oncology annual meeting on upcoming presentation in Chicago.
  • Presented poster outlining mechanism of action of Decoy platform at the American Association for Cancer Research Annual Meeting in April 2024.
  • Reported preliminary positive results from second cohort of Phase 1 trial and initiated multi-dose cohort in March 2024.
  • Announced granting of key patent that helped to further expand intellectual property portfolio in January 2024.

Financial Highlights for First Quarter ended March 31, 2024

Research and development expenses for the three-month period ended March 31, 2024, were $1.6 million, a decrease of $0.3 million, or 15%, compared with $1.9 million in the three-month period ended March 31, 2023. The decrease was primarily due to the manufacturing processes of Decoy20 that were conducted in the three months period ended March 31, 2023.

General and administrative expenses for the three-month period ended March 31, 2024, were $2.4 million, a decrease of $0.2 million, or 9%, compared with $2.6 million in the three-month period ended March 31, 2023. The decrease was primarily due to decreased legal fees, recruitment costs and directors’ and officers’ insurance expenses, and was offset by an increase in payroll and related expenses and investor relations expenses.

Loss per share for the three-month period ended March 31, 2024 was $0.45, compared with $0.51 for the three-month period ended March 31, 2023.

As of March 31, 2024, the Company had cash and cash equivalents of $9.7 million. As of December 31, 2023, the Company had cash and cash equivalents of $13.4 million. The Company expects that its current cash and cash equivalents will support its ongoing operating activities through the third quarter of 2024. This cash runway guidance is based on the Company’s current operational plans and excludes any additional funding and any business development activities that may be undertaken. Indaptus continues to assess all financing options that would support its corporate strategy.

Net cash used in operating activities was $3.9 million for the three-month period ended March 31, 2024, compared with net cash used in operating activities of $4.9 million for the three-month period ended March 31, 2023. The $1.0 million decrease in net cash used was primarily attributable to a decrease in our research and development and general and administrative expenses and was also attributable to a settlement fee that was paid in February 2023.

There was no net cash provided by or used in investing activities in the three months ended March 31, 2024. Net cash provided by investing activities was approximately $2.1 million for the three months ended March 31, 2023, which was related to the maturity of $9.0 million in marketable securities, offset by net investment of approximately $6.9 million in marketable securities.

Net cash provided by financing activities for the three months ended March 31, 2024 was approximately $0.3 million, which was provided by issuance and sale of our common stock under the At The Market Offering Agreement. There was no net cash provided by or used in financing activities in the three months ended March 31, 2023.

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

PUBLISHED

JAN 4, 2024 8:00AM EST

Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc.(Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate stabilized packages of immune agonists to activate both innate (immediate) and adaptive (learned) cellular immune pathways, announces that the European Patent Office (EPO) has informed the company that it will grant a European patent related to the company’s platform technology, covering a composition that can be used in the prevention or treatment of viral infections.

The patent, titled “Methods of Treatment of Infections Using Bacteria,” (Application 19 866 580.4) provides protections for the application of the Company’s Decoy technology platform alone or in combination with standards of care for the prevention or treatment of any viral infection. The EPO patent will be the second patent granted to Indaptus outside the United States for this application.

Jeffrey Meckler, Indaptus Therapeutics CEO, commented, “The continued protection of our intellectual property both in the U.S. and abroad will provide a competitive advantage for the Company, which should ultimately drive significant shareholder value over time. We continue to explore the applications of our technology platform beyond solid tumors, for which we are currently engaged in a Phase 1 clinical trial, and look forward to updating our shareholders on scientific progress.”

‍

Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study

PUBLISHED

NOV 6, 2023 8:00AM EST

Poster presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer Showed Favorable Safety Profile and Achievement of Stable Disease in All Four Patients in First Cohort.

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc.(Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate a stabilized package of immune agonists to activate both innate (immediate) and adaptive (learned) cellular immune pathways, announces interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. A broad expression of cytokines and chemokines associated with innate and adaptive anti-tumor immune responses was observed, while adverse events were generally tolerable and resolved within 30 minutes to three days. Decoy20 is designed to “re-set” the immune system’s response to cancer. The poster was presented on November 4, 2023, at the Society for Immunotherapy of Cancer in San Diego.

“We are impressed that we saw short-term induction of more than 50 cytokines, chemokines and biomarkers and believe this is unprecedented with a single agent. These early data support our long-standing hypothesis that the Decoy platform may induce robust immune responses across multiple types of immune cells that we believe are important for the eradication of solid tumors,” commented Indaptus CEO Jeffrey Meckler.

“The relatively brief duration of exposure to Decoy20 supports our hypothesis of utilizing a “pulse-prime” approach, providing a short period of activation to avoid unwanted toxicities that may occur from prolonged immune activation,” commented Michael Newman, Ph.D., Indaptus Founder and Chief Scientific Officer.

As reported in the poster, trial subjects experienced transient induction of over 50 different biomarkers associated with immune responses, and generally anticipated transient adverse events.After the end of infusion, Decoy20 was cleared from the blood within 30 to 120 minutes. This rapid clearance and associated transient cytokine/chemokine induction are desired to avoid prolonged toxicity, often associated with longer term cytokine exposure. In contrast, therapeutics that are designed to be continuously present over weeks, months, or even years, such as CAR-T, can induce this type of toxicity. Peak cytokine and chemokine induction occurred within ~4 to 24 hours and most returned to baseline by 24-48 hours. Lymphocyte cell populations were transiently reduced in the blood and then rebounded, suggesting that these critical immune cells were redistributing from the circulation to lymph nodes, immune organs or sites of tumor. This supports the hypothesis of an “immune resetting” proposed mechanism of action.

In addition, each of the subjects was observed to have stable disease four weeks after a single dose, with three of them having started the trial with progressive disease.

“We look forward to continuing the trial with the current cohort having a lower dose, given the broad potential immune activation we have observed,” added Roger Waltzman, M.D., Indaptus’ Chief Medical Officer. “We anticipate that in the next stage of the trial we will assess the effect of weekly dosing (as opposed to the single dose in these first two cohorts), while analyzing a host of biomarkers, immune and tumor cells in peripheral blood, and immune cell populations in the tumor microenvironment, coupled with standard radiographic measurements.”

The poster was titled, “Preliminary results of an in progress, first-in-human Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.” First cohort patients received a single dose of 7×107 killed Decoy20 bacteria via a one-hour IV infusion.

‍

NEWS

‍

MANAGEMENT TEAM

JEFFREY A. MECKLER

Chief Executive Officer

Jeffrey Meckler currently serves as our Chief Executive Officer, bringing more than 30 years of financial and healthcare leadership experience to the company. Most recently, Jeff was the CEO of Intec Pharma, and prior to that, CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Earlier in his career, Jeff was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience after its acquisition by Royalty Pharma. Jeff started his career at Pfizer, where he held a series of positions in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. He has also served as a director of QLT, Inc., Cocrystal Pharma, ClearFarma USA, Kyalin Bioscience, and Alveolus, and currently serves as director of Travere Therapeutics, where he also previously served as Chairman. Jeff is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. He holds a B.S. in industrial management, an M.S. in industrial administration from the Tepper School of Business at Carnegie Mellon University, and a J.D. from Fordham University’s School of Law.

MICHAEL J. NEWMAN, PH.D.

Founder and Chief Scientific Officer

A founder of the company, Dr. Michael Newman currently serves as our Chief Scientific Officer. Most recently, he was Founder and CEO of Decoy Biosystems, where he developed the technology that serves as the foundation of Indaptus. With more than 35 years of experience carrying out and managing oncology drug discovery through early development in academia and at pharmaceutical and biotechnology companies, Michael has also served as a consultant to ~35 companies, assisting with target identification and prioritization, management of R&D, fundraising, and in/out-licensing. His previous positions include faculty appointments in biochemistry at Brandeis University and the Roche Institute of Molecular Biology, Senior Associate Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology), Executive Director of Oncology at Novartis Pharmaceuticals (Head of Cancer Biology in the U.S.), and senior management positions at several Biotechnology companies, where he also managed drug discovery programs in inflammation, diabetes, and infectious disease. Michael received a Bachelor’s degree in biology from the University of California at San Diego, a Ph.D. in cell and developmental biology from Harvard Medical School (National Science Foundation Pre-doctoral Fellow) and carried out post-doctoral research at Cornell University.

Walt A. Linscott - Chief Operating Officer

WALT A. LINSCOTT

Chief Operating Officer

Walt Linscott brings more than three decades of global leadership, entrepreneurial and professional experience with broad business development, operational, regulatory, and transactional experience in the Life Sciences sector to his current role as Chief Operating Officer at Indaptus. Most recently, he held the position of Chief Business Officer at the company. Prior to Indaptus he was the Chief Business Officer at Intec Pharma. He is also a Founding executive member of Oxford Strategic Alliance, a multinational business development and referral enterprise for strategic advice, management and investment development/management for individuals and companies that are globalizing. Previously, Walt served as President, COO and General Counsel at Treiber Therapeutics, an anti-viral-focused venture he co-founded. He has also served in a variety of General Counsel and Corporate Secretary roles at Cocrystal Pharma, Carestream Health, and Solvay Pharmaceuticals, where he also led compliance, IP, security, privacy, public affairs and government affairs functions. In addition, he was previously an Associate and Partner at Thompson Hine where he founded the firm’s Atlanta office, served as Partner in Charge, and as Chair of the firm’s Life Science Practice Group. Walt holds a Master of Science in Experimental and Translational Therapeutics with honors from the University of Oxford, a Master’s degree in Global Business from the University of Oxford and Master’s degree in Entrepreneurship from Cambridge University. He earned his J.D. from the University of Dayton School of Law where he served as Managing Editor of the Law Review. After graduating with a Bachelor’s degree from Syracuse University and prior to entering law school, he earned a commission and served on active duty as an Officer in the United States Marine Corps. Walt is also a Certified Flight Instructor and was previously a professional stunt pilot.

ROGER J. WALTZMAN

Chief Medical Officer

Roger Waltzman, M.D., M.B.A. currently serves as our Chief Medical Officer. Dr. Waltzman is a board-certified medical oncologist whose career highlights include the roll of Chief Medical Officer of publicly traded company, Molecular Templates (2019-2023) and multiple senior drug development roles at Novartis Oncology (2007–2013), where he played a leading role in the development of imatinib, nilotinib, and ruxolitinib. From 2013 to 2016, Dr. Waltzman was the Full Development Head of Malaria Drug Development at Novartis. More recently, Dr. Waltzman was CMO at Rgenix (now Inspirna), where he supervised the development of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b. Previously, he served as CSO at Jaguar Health and Napo Pharmaceuticals, where he led scientific aspects of development and commercialization of Mytesi® (crofelemer).

Before joining the industry, Dr. Waltzman held assistant professorships in medical oncology and palliative care at Saint Vincent’s Hospital and Mount Sinai School of Medicine in New York. He completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Waltzman earned a Master of Business Administration at Columbia Business School and a Doctor of Medicine and Bachelor of Arts from Brown University.

Nir Sassi

NIR SASSI

Chief Financial Officer

Nir Sassi currently serves as our Chief Financial Officer, bringing a broad skillset across management, corporate finance, due diligence, accounting, and financial analysis. Prior to joining Indaptus, Nir spent 11 years at Intec Pharma, starting as Vice President of Finance and ending his tenure there as Chief Financial Officer. Previous to that, Nir served as a Senior Manager at PricewaterhouseCoopers Israel for eight years, including two years relocation to the PWC New York office. He is a certified public accountant in Israel and holds a Bachelor’s degree in economics and accounting from Ben Gurion University in Beer Sheva, Israel.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY INDP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

GRYP Profile

Total mining revenue for 2023 of $21.1 million while Total mining revenue in Q1 2024 of $7.5 million, compared to $4.8 million in Q1 2023

Gryphon has authorized a stock repurchase program, allowing for the buyback of up to $5 million of its common stock

In 2023, the company produced 788 bitcoin-equivalent coins. At the present valuation, that’s $48.5 million USD in crypto

Certified 100% renewable energy operation heading into 2024

READ THE INVESTOR PRESENTATION HERE

Hello Everyone,

We have had some explosive profiles over the past few weeks.

You should remember this next one.

We profiled it before a few months back where it saw an average of trade of 1.50 on the session.

Exactly 2 weeks later it hit 1.89 for a 26% move. I hope that you were watching it.

Put GRYP back on your radar Immediately.

Gryphon Digital Mining is a public Bitcoin miner that recently has been listed on the NASDAQ exchange and has established itself as a leader in sustainability and efficiency. Led by Rob Chang, the management team leverages its many years in the public Bitcoin miner space and utilizes an asset-light Business model to compete in this highly competitive industry.

Gryphon Digital Mining has grown significantly in the past three years by adding sustainable hashing power to its operations through strategic partnerships and ASIC fleet upgrades. The company has recently been listed on the NASDAQ exchange through a reverse merger with the public company Akerna.

Gryphon Digital attempted to execute a reverse merger in 2021 with Sphere 3D, a public net carbon-neutral cryptocurrency miner, but they both mutually agreed to not proceed with the merger. Gryphon Digital decided to enter a master services agreement to manage all of Sphere 3D’s blockchain operations for a five year period at a 22.5% gross profit royalty. Although the agreement is through August 2026, Sphere 3D has moved to terminate this arrangement. Gryphon believes that the agreement will continue on despite the litigation and forecasts over $6 million in 2024E revenue from the partnership.

Bitcoin mining involves specialized computers (ASICs) verifying transactions and solving complex mathematical problems to add blocks to the blockchain. Miners compete through computing power to solve these problems, with the first successful miner adding the block and receiving new bitcoins and transaction fees as a reward. The process ensures network security and decentralization, with difficulty adjusting based on how many miners are in the network to maintain a consistent block time. Bitcoin miners are all preparing for the upcoming Bitcoin supply halving which occurs every ~4 years and cuts the rewards given to miners in each block by half. This halving is expected to occur in April 2024, and miners that are operating with inefficient and obsolete fleets will not be able to survive. Historically, inefficient miners have been forced to stop operating because the cost to mine a Bitcoin doubles immediately once the halving occurs since the rewards are halved; so, miners must have a strategic plan to mitigate this. The Bitcoin mining space has already seen some consolidation in the market and many public players like Cleanspark and Marathon are shopping around for smaller companies to acquire for additional cost synergies and computing power. Gryphon Digital Mining is well-positioned to outperform less efficient public miners going into the Bitcoin halving this year and can now utilize the public capital markets for its M&A strategy and rely on its seasoned leadership team that has managed through multiple Bitcoin cycles in the past to execute sustainable growth. Additionally, the asset-light model that Gryphon Digital utilizes will enhance its flexibility and enable the company to respond to new developments in the digital asset ecosystem unlike other larger miners in the space.

Bitcoin’s code enforces a cap of 21 million coins, with 93.5% already in circulation and the remaining 1 million to be gradually distributed over the upcoming century. The mining reward halves every four years, resulting in a diminishing rate of new Bitcoin creation, making it a deflationary asset. Like in previous cycles, the price of Bitcoin has begun to see material gains in the winter period approaching the next halving; miners demand higher prices for the asset since the rewards get halved. After Bitcoin reaches the previous cycle’s all-time-high, price discovery will be unleashed again and the lucrative summer period will start.

Gryphon Digital Mining, Inc. Reports Fiscal Year 2023 Financial Results

LAS VEGAS, NV / ACCESSWIRE / April 1, 2024 / Gryphon Digital Mining, Inc.(Nasdaq:GRYP) (“Gryphon” or the “Company”), a bitcoin mining company that is independently certified to be 100% renewable and pursuing a negative carbon strategy, today reported financial results for its fiscal year ended December 31, 2023.

Rob Chang, CEO of Gryphon, commented, “2023 and the year to date has been a transformational period for Gryphon, culminating in our Nasdaq listing in February. Our positive net cash flow in 2023 and Breakeven Cost (as defined below) per Bitcoin of approximately $18,200 demonstrate our industry leading operational efficiency. Our current self-mining hashrate stands at 0.9 exahash, and we have ambitious plans to expand. Our aim is to quickly reach 10 exahash, propelling us from a smaller player to a significant industry presence – all the while leading the way in financial sustainability and efficiency.”

Mr. Chang added, “Gryphon’s management team, featuring former c-suite executives from industry giants Marathon and Riot, brings industry leading experience and a proven track record of success. With such pedigreed experience, we think we are well-equipped to achieve our goals and establish ourselves as a premier player in the market. In sum, with our strong foundation, operational efficiency, and strategic expansion plans, Gryphon believes it is well-positioned to navigate the challenges of the post-halving landscape, achieve a position as an industry leader, and deliver long-term value to our shareholders.”

Financial Highlights of Fiscal Year 2023

  • Total mining revenue for 2023 of $21.1 million, compared to the prior year $21.4 millionin 2022.
  • Breakeven Cost[1] per Bitcoin in 2023 was $18,217, compared to $14,964 in 2022. The company is focused on Breakeven Costs, which we believe is the best measure of what it costs to mine bitcoin on an operating basis. Some of our peers only focus on electricity costs and leave out the other costs to mine. We believe that a focus on the Breakeven Costs to produce a bitcoin at the mine level has the potential to offer the transparency needed to compare operations on an apples-to-apples basis.
  • The Company recognized a net loss for the year of ($28.6) million, which includes non-cash expenses of $36.5 million. Non-cash expenses mainly consisted of depreciation, non-cash machine impairment and the non-cash notional valuation of the company’s BTC loan. This compares to net income in 2022 of $3.5 million, which was also subject to non-cash expenses, and benefited from $24.5 million in non-cash gains due to a non-cash gain on the extinguishment of debt and the non-cash notional valuation of the company’s BTC loan.
  • Adjusted EBITDA[2] was $4.8 million, compared to $7.4 million in the prior year.

[1] The Company defines Breakeven Cost per Bitcoin as (a) Cost of Revenues (excluding depreciation) divided by (b) total bitcoin generated and received from the hashrate contributed to the mining pool operator. The Company mined approximately 739 and 815 Bitcoin, respectively for the year ended December 31, 2023 and 2022, respectively.[2] The Company defines Adjusted EBITDA as (a) GAAP net income (loss) plus (b) adjustments to add back the impacts of (1) depreciation and amortization, (2) interest expense, (3) income tax expense (benefit) and (4) adjustments for non-cash and non-recurring items which currently include (i) stock compensation expense, (ii) impairments of miners pursuant to ASC 360, (iii) impairments of digital currency pursuant to ASC 350 (iv) realized gain from use of digital assets as it relates to the bitcoin denominated note payable and (v) gain/loss on debt extinguishment.

Balance Sheet Highlights as of December 31, 2023

Assets

  • Cash and cash equivalents: $915,000
  • Bitcoin: 67.2
  • Total current assets: $5.4 million
  • Total mining assets (including deposits & intangible assets): $13.4 million
  • Total assets: $18.8 million

Liabilities and Stockholders’ Equity

  • Current liabilities: $19.4 million
  • Total liabilities: $19.4 million

As of February 29, 2024, the Company had cash holdings of $1.4 million, Bitcoin holdings of approximately 60.4 Bitcoin with a fair market value of $3.7 million and 330.3 Bitcoin of Bitcoin denominated debt.

2024 Outlook

Based on an average price of Bitcoin of $70,000 and an average network hashrate of 550 exahash for 2024, we are currently projecting gross profit of approximately $16.6 millionfrom mining operations. We have posted a gross profit sensitivity analysis in our investor presentation, which can be found on slide 14 of our investor deck on our company website.

Sphere 3D Litigation

On March 25, 2024, Gryphon filed a motion with the United States District Court for the Southern District of New York seeking permission to file a motion for prejudgment attachment, seeking to secure $10 million in equity proceeds that Sphere recently received from a settlement related to Core Scientific’s bankruptcy exit. We want to ensure that the funds are available to satisfy any judgment we may receive due to Sphere’s breach of contract, where it entered into at least four hosting agreements with other providers, violating the exclusivity clause of its agreement with Gryphon. We are seeking damages amounting to at least $30 million. Over the last four months, Sphere has revealed its growing financial troubles. On November 28, 2023, in a filing in the Core Bankruptcy Action, Sphere’s counsel acknowledged that the company was operating with a $200 million net loss and that recent losses had overtaken revenue by a two-to-one margin. Sphere’s stated rationale for terminating the contract – that a malicious actor had diverted bitcoin transfers from Sphere to a third party – was not only unfounded, but was, in fact, evidence of gross negligence on the part of Sphere that allowed activities from malicious actors where Gryphon became the victim. Gryphon engaged an independent third-party security firm who confirmed that Gryphon’s systems were not compromised.

Gryphon Digital Mining Announces April Operational Update

Machine Upgrades Lead to New Company All-Time Bests in Hashing Power and Efficiency

LAS VEGAS, NV / ACCESSWIRE / May 6, 2024 / Gryphon Digital Mining, Inc. (NASDAQ:GRYP) (“Gryphon” or the “Company”), a bitcoin mining company that is independently certified to be 100% renewable and pursuing a negative carbon strategy, has released its unaudited operational update for April 2024.

Key highlights for the month:

  • Produced approximately 40 bitcoin
    • Approximately $2.6 million in value based on an average April bitcoin price of $66,183
    • Production of 1.33 BTC/day on average, or about $88,244/day
  • Achieved bitcoin efficiency of 43 BTC/EH
  • New Company record average self-mining hashing power of 914 PH/s in April
  • Machine upgrade program completed with the installation of Bitmain S21 200 TH/s machines
  • 21 bitcoin in treasury as of April 30, 2024
  • Average machine efficiency improved to 28.7 J/T in April
  • Scope 1 and Scope 21 operations continue to be 100% electrified by zero-carbon emitting Hydro power

“April signified the beginning of our post go-public improvement program as we ordered and installed a batch of state-of-the-art Bitmain S21 200 TH/s machines to upgrade our mining fleet. The result of this effort was a new Company all-time high in average hashing power at 914 PH/s as well as a new Company all-time best in average mining efficiency at 28.7 J/T as our new machines are currently tracking to be 43% more efficient than the machines they replaced,” noted Rob Chang, CEO of Gryphon. “For the month, we earned bitcoin valued at approximately $2.6 million based on an average bitcoin price of $66,183, which includes record setting days when bitcoin mining transaction fees were particularly valuable.”

April’s bitcoin efficiency performance of 43 BTC/EH continues to showcase Gryphon’s commitment to running its operations at peak performance. In monthly rankings over the last twelve-months, Gryphon ranked #1 in bitcoin efficiency on six occasions. Since Gryphon commenced operations in September 2021, it has consistently placed among the top of these publicly available bitcoin efficiency scores – ranking at or tied for first in 17 of the 31 months, or about 55% of the time.

The Company held 21 bitcoin in its treasury as of the end of April as coins were sold to finance the mining fleet upgrade in a non-dilutive manner.

Conference Schedule:

  • Consensus 2024 by CoinDesk held in Austin, TX on May 29 th – 31 st
  • Mining Disrupt in Miami, FL on June 24 th – 26 th
  • Bitcoin 2024 held in Nashville, TN on July 25 th – 27 th
  • Blockchain Futurist Conference in Toronto, ON on August 13 th – 14 th

Gryphon Digital Mining Announces Stock Repurchase Program; Machine Upgrade Program Completed Ahead of Schedule

LAS VEGAS, NV / ACCESSWIRE / April 22, 2024 / Gryphon Digital Mining, Inc. (Nasdaq:GRYP) (“Gryphon” or the “Company”), a leading bitcoin mining company that is independently certified to be 100% renewable and pursuing a negative carbon strategy, is pleased to announce a new share buyback program, authorized by its Board of Directors (the “Board”), and the completion of its machine upgrade program ahead of schedule.

Stock Repurchase Program

This strategic move allows for the repurchase of up to $5 million of Gryphon’s common stock, underscoring its ongoing commitment to enhancing shareholder value.

“This share buyback program authorization demonstrates the Board and management team’s confidence in Gryphon’s strategy and commitment to shareholder value creation while maintaining a balanced approach to capital allocation moving forward. From our track record of ranking at the top of peer bitcoin efficiency charts throughout our operational existence and being among the lowest cost producers of bitcoin at ~$18,200per bitcoin in 2023, our dedication towards shareholder friendly decisions is relentless.” said Rob Chang, CEO, President, and Director. “The authorization of a share buyback program is a key initiative that we expect to create long-term value for shareholders. In an industry where share sales are common, Gryphon is showing that share capital management goes both ways.”

The buyback program does not obligate the Company to purchase any particular number of shares and there is no guarantee as to the exact number of shares that will be repurchased by the Company. The program may be suspended, modified or terminated by the Company at any time and for any reason, without prior notice.

Miner Upgrades Completed Ahead of Schedule

Mr. Chang added, “We have completed our miner upgrade program ahead of schedule, which is set to significantly boost our operational efficiency. Our previously announced batch of Bitmain S21 200 TH/s miners that were ordered to replace a portion of our older fleet of machines are now deployed. This improvement is expected to add approximately 23 PH/s to our hashing power and improve our average fleet efficiency to 28.5 J/T. Gryphon’s self-mining hashrate now stands at approximately 0.94 EH/s.”

NEWS

Gryphon Digital Mining, Inc. Reports First Quarter 2024 Financial Results1 day agoGryphon Digital Mining to Host First Quarter 2024 Earnings Conference Call2 days agoGryphon Digital Mining Announces April Operational UpdateMay 6, 2024Gryphon Digital Mining Announces Stock Repurchase Program; Machine Upgrade Program Completed Ahead of ScheduleApr 22, 2024Gryphon Digital Mining Announces March Operational UpdateApr 4, 2024Gryphon Digital Mining to Participate in Upcoming Investor ConferencesApr 3, 2024Gryphon Digital Mining, Inc. Reports Fiscal Year 2023 Financial ResultsApr 1, 2024Gryphon Digital Mining Reschedules Q4 and FY 2023 Earnings Call to Tuesday, April 2 at 9:00am ETMar 27, 2024Gryphon Digital Mining Publishes Carbon Emissions Assessment Proving its 100% Renewable StatusMar 25, 2024Sphere 3D Corp. Provides February 2024 Production and Operation UpdatesMar 22, 2024Gryphon Digital Mining to Host Fourth Quarter and Year End 2023 Earnings Conference CallMar 21, 2024Gryphon Digital Mining Announces Participation in 36th Annual Roth ConferenceMar 12, 2024Gryphon Digital Mining Announces February Operational UpdateMar 11, 2024Gryphon Digital Mining Announces January Operational UpdateFeb 13, 2024

‍

MANAGEMENT

ROB CHANG

CEO, President, & Director

Rob is an experienced executive who most recently was the CFO of Riot Blockchain and has consulted for other publicly traded blockchain mining companies. He has over 25 years of experience in the financial services industry including serving as the Managing Director and Head of Metals & Mining at Cantor Fitzgerald where he was recognized by Bloomberg as the Best Precious Metals Analyst in Q1 2016. His career achievements include rescuing a NASDAQ-listed company from bankruptcy despite regulatory and industry headwinds. Mr. Chang is frequently quoted and a regular guest of several media outlets including Bloomberg, Reuters, CNBC, and The Wall Street Journal. Mr. Chang also previously served as Director of Research and Portfolio Manager at an investment firm that managed $3 billion in assets. He currently sits on the boards of Ur-Energy and Fission Uranium. Mr. Chang completed his MBA at the University of Toronto’s Rotman School of Management.

VIEW TEAM

‍

‍

‍

‍

‍

SIM SALZMAN

CFO

Sim Salzman is a results-oriented Chief Accounting/Financial Officer with over 20 years of experience in public and private accounting serving clients in the cryptocurrency, hospitality, retail, food and beverage, gaming, non-profit, residential and commercial construction, real estate and low-income housing industries.

He has over two years of experience as the Chief Financial Officer and Chief Accounting Officer of one of the largest bitcoin mining Companies that grew its market cap from $500 million to approximately $8 billion within my first twelve months. There I was responsible for implementing a new accounting system, streamlining financial processes, improving efficiency and accuracy of financial reporting, forecasting, and budgeting, building a lean but high-performing financial team, and collaborating closely with senior management to align financial goals with overall business objectives while maximizing shareholder returns. Utilized the capital and debt markets to raise over $2 billion in liquidity for operational purposes.

Sim has experience as the Chief Financial Officer of a growing media and hospitality organization responsible for implementing core competencies and timely analytical reviews. Embraced multiple roles while leading a corporate restructuring that positively impacted the top and bottom line.

Five years’ experience with one of the country’s leading hospitality development and management companies as the Corporate Controller responsible for over $215M in annual revenues across 20 venues located on the Las Vegas Strip.

Sim set up policies and procedures for State and Federal compliance in regards to filing deadlines such as Unclaimed Property, Form 1042, Sales & Use Tax, Commerce and Modified Business Tax. Dealt directly with the external Tax Firm to file various annual 1065’s and liaison to the IRS for research and guidance on any pertinent issues.

Sim’s prior experience includes working for eight years in public accounting with four leading firms with clients in various industries. Passed the Uniform CPA Exam.

VIEW TEAM

CHRIS ENSEY

Chief Technical Advisor

Chris is a leading expert in crypto data centers and has consulted North America’s largest public mining firms on building successful operations. He is a technology executive with a career spanning blockchain, cybersecurity, and enterprise software. His mix of technical and business acumen has led to successful leadership roles including acting CEO and COO of Riot Blockchain, CTO of BlueVoyant and COO and founder of Dunbar Cybersecurity. Mr. Ensey has 25 years of experience developing mission-critical software with an emphasis on large data, analytic processing, and cloud technologies. He has driven numerous products to market, including solutions for managed security services, cyber risk management, and digital healthcare. He began his career as a system engineer and integrator working on national intelligence and defense programs with SAIC. Chris has a bachelor’s degree in Computer Engineering from Virginia Tech.

‍

‍

‍

‍

‍

‍

BRITTANY KAISER

Chair of the Board

Brittany Kaiser is an entrepreneur, activist, and globally recognized expert in data protection and privacy. As Co-Founder of the Own Your Data Foundation, she teaches digital literacy education and training to governments, corporates, and families. She is also a Co-Founder of the Digital Asset Trade Association (DATA) for legal advocacy where she does legislative drafting and lobbying on privacy and blockchain laws. Ms. Kaiser sits on the board of many companies across industries, working on data ethics, compliance, and privacy protocols. Ms. Kaiser is also the author of Targeted published globally by Harper Collins, and she is the main subject of Netflix’s original documentary “The Great Hack”, nominated for an Emmy, BAFTA, and shortlisted for an Oscar. As a renowned thought leader and public speaker, Ms. Kaiser is represented by CAA and has spoken at prestigious events at the United Nations, the European and British Parliaments, the G20, and WebSummit, as well as guest lecturing at universities such as Harvard, Oxford, and Columbia.

‍

‍

‍

‍

‍

‍

STEVE GUTTERMAN

Director

Steve has built, led, acquired and invested in market-changing companies for 25 years. He is currently the CEO of Falcon International, one of the largest private cannabis companies in California.

Previously, he served as President of Harvest, since acquired by Trulieve to form the largest cannabis company in the US as measured by revenue. Prior to Harvest, he held a variety of senior roles including at E*TRADE Financial, where he was EVP and COO of E*TRADE Bank, where he was instrumental in the Bank’s growth from $1 billion in assets to $35 billion. He was the CEO of GeoPoll, a leading market research company in developing world countries, and was Managing Director of MBH Enterprises, a private equity company focused on technology and infrastructure investments. He holds a JD/MBA from Columbia University and a BA from Tufts University.

‍

‍

‍

‍

‍

‍

‍

HEATHER COX

Director

Heather Cox was most recently the Chief Digital Health and Analytics Officer for Humana. In this role, Heather was accountable for building Humana’s digital care delivery operations and leading enterprise advanced analytics, including the application of Artificial Intelligence at scale in healthcare.

Prior to joining Humana, Heather served as Chief Technology and Digital Officer at USAA, where she led the teams responsible for designing and building personalized and digitally enabled end-to-end experiences for USAA members. Heather has also designed, built, and served as CEO of Citi FinTech at Citigroup, building a fintech start-up that allowed the company to harness the innovation in the global fintech ecosystem and to adapt to a future dominated by mobile technology. Before that she, headed Card Operations for Capital One.

Heather was named by American Banker magazine as the #3 Woman to Watch nationally in banking by American Banker Magazine in October 2017. She was also named to American Banker’s Women to Watch list in 2011, 2013 and 2016. In 2015, she was named one of the 10 Most Innovative CEOs in Banking by Bank Innovation, as well as Digital Banker of the Year by American Banker. In 2018, Heather was appointed to the NRG Energy Board of Directors and was elected to the Atlantic Union Bankshares Board of Directors in August 2022.

‍

‍

‍

JESSICA BILLINGSLEY

Director

Jessica is a seasoned executive and innovator with decades of experience in frontier technology. She is named on multiple patents including advancements in supply chain technology and anti-counterfeit solutions using blockchain and NFTs. Her experience includes leading successful public and private companies as CEO and serving on multiple boards of directors. Jessica possesses in-depth expertise in private and public capital markets and has successfully navigated complex transactions to drive growth and business transformation. She is also FINRA securities licensed.

Previously, as Founder, Chairman of the Board, and CEO of Akerna (Nasdaq: KERN), a Software as a Service ag-tech company, she successfully publicly listed, completed multiple accretive acquisitions, maintained market leadership for over a decade, and exited via strategic acquisition. Jessica currently serves on the boards of Gryphon Digital Mining (NASDAQ:GRYP), Nu Energy (NASDAQ:NXU), OARO, and the Young President’s Organization (YPO) Entrepreneurship Network Board.

She has been recognized with numerous awards, including Inc. Top 100 Female Founder and Fortune’s Most Promising Woman Entrepreneur. Her insights and thought leadership have been featured in numerous prominent media outlets, in addition to her active contribution to Entrepreneur and Rolling Stone publications.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY GRYP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

SYTA

2023 Revenue was $8.2 Million, a year of strong growth and expansion for Siyata Mobile. Revenue increased 27% and gross margin increased 92% over 2022

SIYATA MOBILE ANNOUNCES NEW ORDERS TOTALING OVER $2.2 MILLION; SD7 ACHIEVES ‘STOCKED’ STATUS WITH THIRD MAJOR U.S. WIRELESS CARRIER

READ THE COMPANY PRESENTATION HERE

https://twitter.com/SiyataMobile/status/1790400108720161106?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1790400108720161106%7Ctwgr%5Ed40b778a6f613422310530ef3ca723cba4ce6919%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.insiderfinancial.com%2Fprofile%2Fsyta222

___________________________

Hello Everyone,

Todays profile closed up near the high of the day after making a strong double digit move.

We have another company that we want you to look at for tomorrow’s session.

This one has been on the move over the past week or so since the company started to release several different news announcements.

Pull up SYTA immediately.

Siyata Mobile Inc. (NASDAQ: SYTA) is a leading global developer and provider of Push-to-Talk Over Cellular (“PTT/PoC”) systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world’s first 3G connected vehicle device as well as the world’s first 4G/LTE vehicle-mounted smartphone for First Responders and commercial fleets and vehicles, thereby creating a new category in the cellular device market with a dedicated smartphone tailor-made for the commercial vehicle market.

Siyata’s suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company’s flagship product, the Uniden UV350, is the world’s first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada’s largest LTE network and PTT community, as well as AT&T in the U.S. Further expanding its availability, Siyata is completing network approval with another U.S. Tier 1 operator to launch the UV350 in Q3 2019.

Despite Siyata’s small size, no other competitor offers as comprehensive of a portfolio of products. Siyata Mobile Inc. (Nasdaq: SYTA) provides disruptive solutions aimed at the Push-to-talk-over-Cellular (PoC) industry, with three complementary product categories targeted to the same core channels and customers. Large global telecommunications customers provide potential rapid entry into a $50 billion North American market.

You will notice the move that this one has made off of its recent lows, under $2.

Siyata Mobile SD7 Mission Critical Push to Talk Over Cellular Device Featured

UScellular Keeps Business and Government Customers Connected with Intuitive Mission Critical Push to Talk Solution

“Siyata’s SD7 rugged Mission Critical Push to Talk over cellular radio handset is an industry leading device that offers UScellular business customers an alternative to land-mobile radios,” By Kim Kerr, senior vice president, enterprise sales and operations for UScellular.

While State And Local Budgets Experience A Squeeze, Siyata Mobile Provides Police With Affordable And Modern Communication Technology

Siyata’s unique approach of offering an affordable mission-critical PTT over Cellular handset that looks and operates like a two-way radio may allow first responder agencies to equip more of their staff than ever before with a reliable and easy-to-use handset to keep more staff connected. With a track record as a pioneer in the industry and with solutions catering to various uses in areas with and without strong cellular coverage, Siyata has earned a solid reputation for reliability and versatility. With rising budget cuts, this maybe solution that state and local governments are looking for.

As a leading developer and distributor of cutting-edge Mission Critical Push to Talk Over Cellular (PoC) devices, including its flagship products, the SD7 Handset and VK7 Vehicle Kit, Siyata is aiming to revolutionize the way industries worldwide connect and collaborate.

In a rapidly evolving landscape, the SD7 Handset stands out to us as the pinnacle of next-generation communication solutions. Designed to seamlessly integrate with existing systems while offering unparalleled functionality, the SD7 stands to bridge the gap between traditional two-way radios and modern cellular networks. Its reportedly rugged design, military-standard durability, and nationwide coverage is designed to ensure reliability and effectiveness across various verticals, from first responders to construction teams.

Complementing the SD7 is Siyata’s innovative VK7 Vehicle Kit, working to transform any vehicle into a mobile communication hub. With its reportedly seamless integration, robust features, and reliable connectivity, the VK7 is designed to enhance safety and efficiency for commercial fleets, emergency responders, and more.

According to Siyata Mobile, it’s not just disrupting the market; it’s setting new standards for communication excellence. With a track record of exponential growth, a strong presence in key global markets, and a visionary leadership team, we see this as an attractive investment for investors interested in the future of communication technology

Top Reason to have SYTA on your radar

  • Market Disruption: Siyata Mobile (NASDAQ: SYTA) is poised to disrupt the multi-billion-dollar Land Mobile Radio (LMR) industry with its cutting-edge Mission Critical Push to Talk Over Cellular (PoC) technology
  • Next-Gen Communication: With the SD7 and VK7, Siyata offers next-generation communication solutions that bridge the gap between traditional two-way radios and modern cellular networks.
  • Innovative In-Vehicle Solutions: The VK7 Vehicle Kit is designed to transform any vehicle into a mobile communication hub, enhancing safety and efficiency for commercial fleets and emergency responders
  • Global Reach: Siyata operates in key geographies including the United States, Canada, Europe, Australia, and the Middle East, offering solutions tailored to diverse market needs.
  • Rapid Industry Growth: The Mission Critical Push to Talk Over Cellular (PoC) industry is experiencing rapid growth, with a forecasted global PoC growth of approximately 9.4% CAGR, reaching approximately $6.95 billion by 2027
  • Strong Market Position: With a full-year 2023 revenue of $8.2 million, up 27% year-over-year, Siyata demonstrates its ability to capture market share and deliver consistent growth.
  • Comprehensive Product Portfolio: From rugged handsets to in-vehicle devices, Siyata offers a comprehensive product portfolio to cater to the communication needs of various industries, including first responders, hospitals, schools, security, construction, and hospitality
  • Visionary Leadership: Led by CEO Marc Seelenfreund and a seasoned management team, Siyata is guided by a vision of innovation, excellence, and market leadership in communication technology
  • High Growth Earnings: SYTA is expected to become profitable in the coming quarters.
  • High Growth Revenue: SYTA’s revenue is forecast to grow dramtically in 2024 and beyond
https://twitter.com/SiyataMobile/status/1777432316081586616?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1777432316081586616%7Ctwgr%5Ed40b778a6f613422310530ef3ca723cba4ce6919%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.insiderfinancial.com%2Fprofile%2Fsyta222

SD7: A Game-Changer in Mission Critical Push to Talk Over Cellular Technology!

SIYATA SD7

Siyata Specializes in Rugged PTT Handsets: SD7 is its Next Generation PoC Handset Complementing its Portfolio of Disruptive Handsets

THE SD7 IS A GAME CHANGER

A Perfect Upgrade from land mobile radio (LMR):

  • forwardA simple, purpose built, highly functional and rugged Android-based PTT only handset
  • forwardRugged IP68 rated design protects against dust and debris
  • forwardExcellent sound quality allowing for clear communication in the presence of background noise
  • forwardAll the benefits of PoC without the headaches of managing the current generation of rugged smartphones and feature phones
  • forwardRobust Next Gen 5G product portfolio coming

The Evolution of ptt

  • double_arrowStay connected wherever you use a mobile phone or Wi-Fi
  • double_arrowMilitary Standard 810H and IP68 ratings
  • double_arrowCost effective PTT cellular rate plan
  • double_arrowMission Critical PTT – QCI’s 65, 66, 69 70

Rock solid Performance

  • double_arrowA simple, functional and rugged Android-based PTT-only device
  • double_arrowRugged IP68 rated design protects against dust, debris and liquids
  • double_arrowSuperior sound quality for clear communication despite background noises
  • double_arrowAll the benefits of cellular with none of the headaches of today’s smartphones
https://www.youtube.com/watch?v=AftgMN3akY4
https://www.youtube.com/watch?v=jFiCIKsxp2s

‍

NEWS

Tue May 14th, 2024

  • SIYATA MOBILE ANNOUNCES NEW ORDERS TOTALING OVER $2.2 MILLION; SD7 ACHIEVES ‘STOCKED’ STATUS WITH THIRD MAJOR U.S. WIRELESS CARRIER

Mon May 13th, 2024

Fri May 10th, 2024

Thu May 9th, 2024

Wed May 8th, 2024

Mon Apr 8th, 2024

Fri Apr 5th, 2024

Thu Apr 4th, 2024

Thu Mar 21st, 2024

Mon Mar 11th, 2024

Tue Mar 5th, 2024

Thu Feb 22nd, 2024

Tue Feb 6th, 2024

Thu Feb 1st, 2024

Mon Jan 29th, 2024

Mon Jan 22nd, 2024

Wed Dec 20th, 2023

Tue Dec 12th, 2023

Thu Dec 7th, 2023

Thu Nov 30th, 2023

Mon Nov 27th, 2023

‍

MANAGEMENT TEAM


Marc Seelenfreund – CEO

Founder and CEO of Siyata . Prior to establishing Siyata Mr. Seelenfreund was a VP at Sunrise Corporation in New York focusing on financing publicly traded technology companies. Mr. Seelenfreund has a law degree and is a board member at a leading private university.

Gerald Bernstein – CFO

Mr. Bernstein spend 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. Mr. Bernstein holds a Bachelor of Commerce as well as a Graduate Diploma in Public Accountancy- both from McGill University. Member of the Canadian Institute of Chartered Accountants since 1987 and a professional chartered accountant.

Glenn Kennedy – VP Sales

Mr. Kennedy has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Mr. Kennedy has managed sales nationally for Motorola Canada, HTC Communications Canada and Sonim Technologies. Mr. Kennedy holds an Bachelor of Arts in Honors Business Administration from the Richard Ivey School of Business at the University of Western Ontario.

DIRECTORS

Peter Goldstein, Chairman of the Board

With over 30 years of diverse and global entrepreneurial, client advisory and capital market experience, Mr. Goldstein has a successful track record in leading and building companies in the capital markets. Mr. Goldstein has achieved capital market objectives by drawing on his strengths in M&A, strategic planning and transaction structuring, as well as his own entrepreneurial success. He has steered and completed initial public offerings (IPO), uplisting and reverse merger transactions, secured private placements and designed successful crowdfunding campaigns. Mr. Goldstein advised the Company on its recently upsized $12.6 Million U.S. Initial Public Offering and listing on the NASDAQ.

Stephen Ospalak, Board Member

Over 20 years in telecom, currently SVP Marketing & Operations at BMG Inc. Served as interim CEO for AiTelecom; Global Integration Officer for Virgin Management Inc.; Canadian VP & Board Advisor for Brightstar, and as SVP Operations at Iusacell. Served as VP of Products & Services at Telus Communications Inc. responsible for an annual spend > $US 1billion in wireless & wireline equipment. Led the planning and execution of Clearnet’s market debut and nationwide launch of the iDEN and PCS Cellular services, setting the North American PCS launch record. Held management positions at AT&T.

Michael Kron, Board Member

Mr. Kron has over 20 years of experience in investment and corporate finance, currently chairman and CFO at AnywhereCommerce Inc. He also co-founded Zellers Optical Centers and played a key role in the sale to Vision Associates of Atlanta. He was the co-founder and CFO of Miazzi Ventures where he founded Mamma.com Inc and later sold to Intasys Corporation at a $44M valuation. Mr. Kron holds a Bcomm from Concordia University as well as a Graduate Diploma in Public Accountancy from McGill University. He has been a member of the Canadian Institute of Chartered Accountants since 1987.

Lourdes Felix, Board Member

Lourdes Felix is a corporate finance executive offering over fifteen years of combined experience in public accounting and in the private sector in building, leading, and advising corporations through complex restructurings. Ms. Felix was previously the controller for a mid-size public accounting firm for over seven years and was responsible for the operations and financial management of regional offices. Ms. Felix has been a Director of BioCorRx Inc. since March 7, 2013. Ms. Felix was appointed Chief Executive Officer of BioCorRx on November 9, 2020 and became Chief Financial Officer of BioCorRx on October 1, 2012. Ms. Felix was President of BioCorRx from February 26, 2020 until she resigned upon her appointment as CEO on November 9, 2020. Ms. Felix holds a Bachelor of Science degree in Business Management and Accounting from University of Phoenix.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND FIVE HUNDRED USD BY SICA MEDIA LLC FOR A ONE DAY SYTA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

NNVC

Targeted Virus-Killing Nanomedicines (PRNewsFoto/NanoViricides, Inc.)

As of December 31, 2023 NNVC had cash and cash equivalent current assets balance of approximately $5.31 Million

This Innovative Biotech Company Is Taking A Novel, Game-Changing Approach To Eradicating Many Respiratory Viruses Once And For All Including Tripledemic Threat Of COVID, RSV, FLU…

ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides, Inc has a more innovative approach that works even when viruses mutate

READ THE INVESTOR PRESENTATION HERE

___________________________

Hello Everyone,

As biotech stages a big comeback, NanoViricides, Inc. (NYSE American: NNVC) looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.

NanoViricides, Inc. (NYSE American: NNVC) is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!

Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031.

NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient’s immune system, thereby making them effective for populations that include geriatric and pediatric patients.

Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..

Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.

NNVC is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-CoV-2 for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Our other advanced candidate is NV-HHV-1 for the treatment of Shingles (previously referred to as NV-HHV-101). The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-CoV-2 into Phase I/II human clinical trials. NV-CoV-2 is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-CoV-2 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses and/or enteroviruses if the initial research is successful. The Company’s technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

RECENT COMPANY HIGHLIGHTS:

    • NanoViricides, Inc’s lead drug, NV-387, is in Phase 1 clinical trials.
    • Broad spectrum antiviral NV-387 showing promise against many virus families including and beyond Tripledemic (i.e. COVID-19, RSV, FLU) .
    • No adverse events in Phase I SAD and MAD studies even at the highest dose 40mg/Kg
    • Found to be non-immunogenic, non-mutagenic, non-allergenic, and non-phototoxic.
    • Strong safety allows use in pediatrics, adults with co-morbidities, and immune-compromised patients unlike limitations of products currently in the market.  
    • Developed Oral Syrup and Oral Gummies (soft solids) – good for geriatric and pediatric patients
    • Drugs expected to continue to be effective even as the virus generates variants – unique receptor site doesn’t change
    • Technology mimics unique receptor site used by virus; delivers to specific targets using receptor-recognition (no bulky antibodies)

A New Era in Targeted Anti-Viral Therapeutics

NanoViricides rang the opening bell of the New York Stock Exchange on Aug. 13, 2014. In the front center (left to right) are Meeta Vyas, Anil Diwan and Dr. Eugene Seymour.

NanoViricides, Inc. is a globally leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.

Our anti-viral therapeutics, that we call “nanoviricides®” are designed to appear to the virus like the native host cell surface to which it binds. Since these binding sites for a given virus do not change despite mutations and other changes in the virus, we believe that our drugs will be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given virus, provided the virus-binding portion of the nanoviricide is engineered appropriately. Viruses would not be able to escape the nanoviricide by viral mutations since they continue to bind to the same cellular receptor and thus would be captured by the nanoviricide. Virus escape by mutations is a major problem in the treatment of viral diseases using conventional drugs.

Versatile Platform Technology

A nanoviricide is created by chemically attaching a virus-binding ligand, derived from the binding site of the virus on its cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a virus mutates

Tailor-made design and selection of (1) the virus-binding ligand; and (2) the backbone “nanomicelle”, separately, allows us to rapidly optimize drug candidates (a) against a number of viruses; (b) for desired pharmacokinetic characteristics (e.g. sustained effect); and (c) for different routes of administration. This versatility is unmatched in the Industry.

Virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands

Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg. This is similar to antibiotics such as penicillin against bacteria that exploit a feature common to all bacteria.

A NanoViricide® Attacking a Virus Particle: Unique, Novel, Nanotech Design

bindingimage

A single nanoviricide micelle may be capable of completely engulfing a Virus Particle. Nanoviricide micelles self-assemble from multiple chains. A single chain micelle shown for convenience. Illustration not to scale.

Each nanoviricide drug is designed as an antiviral agent specifically targeted for a particular type of virus or group of viruses. Most existing anti-viral agents are known to have non-specific effects against both host cells and viral machinery at the same time often leading to side effects. Most current anti-viral agents act inside human cells. It is believed that this intracellular mechanism leads to significant opportunities for unwanted side effects against host cells. Nanoviricides, on the other hand, are designed to work directly against virus particles in bodily fluids. The Company believes that this approach may make nanoviricides inherently safer than existing approaches.

A nanoviricide is designed to seek and attach to a specific virus particle, engulfing the virus particle in the process, thereby rendering it incapable of infecting new cells, and disabling it completely. This suggested mechanism of action encompasses much more than what the current entry and fusion inhibitors are expected to do. The fusion and entry inhibitors do not completely cover the virus particle, likely blocking only a few sites on the virus particle. This means the virus particle may still be capable of infecting cells using its unblocked attachment sites. In contrast, a nanoviricide, because of its larger size and flexible nature, is expected to engulf the virus particle completely, thus disabling the virus particle. The action of a nanoviricide, if it works as designed, may be expected to be superior to antibody agents that attack viruses. Antibodies, being large, are expected to block relatively greater portions of the virus particle surface compared to small molecule entry inhibitors. However, antibodies depend upon the human immune system responses for clearing the virus particle. In contrast, nanoviricides are thought to be capable of acting as completely programmed chemical robots that finish their task of destroying the virus particle on their own.

NV 387 IN CLINICAL TRIALS

The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with NO adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus.

Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects.

The clinical trials involved both oral tablets and oral gummies, catering to various age groups, including pediatrics. NV 387 exhibited broad-spectrum activity against multiple strains of coronaviruses, showcasing effectiveness 10 times greater than remdesivir in preclinical studies.

The ongoing clinical trial progress and positive results position NanoViricides at the forefront of antiviral drug development, marking a significant milestone in their journey from preclinical research since 2005 to clinical trials.

The company believes that NV-387 not only binds to the virus, but fuses with the virus surface, uprooting the glycoproteins that are required for the virus to bind to the human cell (for example, the S protein, and its products S1 and S2 proteins from coronaviruses), thereby rendering the virus incapable of infecting a cell. In contrast, antibodies are only capable of covering the virus, generally incompletely, and require immune system assistance for clearing the resulting complex!

NV-387 ADDRESSES AN UNMET MEDICAL NEED FOR BROAD-SPECTRUM, SAFE AND EFFECTIVE ANTIVIRAL DRUG THAT WORKS AGAINST MULTIPLE VIRAL THREATS:

There is a significant unmet medical need for a broad-spectrum antiviral drug that is effective and useable in all segments of the population. There are substantial limitations for all currently approved COVID drugs in terms of both the eligibility of a COVID patient, and the effectiveness of the drug.

NNVC believes that the excellent safety and the distinctly different mechanism of NV-CoV-2 (NV-387) support the use of this drug across all patient populations. This is an important characteristic for a COVID drug as well as for a drug to treat RSV infection.

NV-387 ADDRESSES LARGE MARKET SIZES:

Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031*.

*Source: Transparency Market Research

The market size for RSV therapeutics was estimated to be $2 Billion in 2023 and is expected to rise to exceed $8.5 Billion by the year 2031**.

**Source: Growth+ Market Reports.

NANOVIRICIDES TECHNOLOGY WILL TRANSFORM THE WAY VIRUSES & THEIR VARIANTS ARE TREATED WORLDWIDE!

NNVC’s novel approach has already enabled variant-proof drugs, blocking the complete viral life cycle without requiring help from the host’s defense systems! If both the viral re-infection cycle, and viral replication cycle arms of the viral lifecycle are blocked, a cure for many viral diseases is possible!!

The Company’s virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands.

Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is also developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg.

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox – NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides

SHELTON, CONNECTICUT – Wednesday, May 8, 2024 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the “Company”), a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against orthopoxvirus family (Smallpox/Mpox), with both inhalation and skin abrasion (sexual) modes of infection acquisition. Ectromelia virus infection of mice is a model for Smallpox infection in humans, and also serves as a surrogate for MPox infection in humans. All three viruses belong to the orthopoxvirus family.

NanoViricides reports that in a lethal animal model of lung infection by Ectromelia virus, oral dosing with NV-387 led to an increase in lifespan of mice that was comparable to oral treatment with tecovirimat (TPOXX®, SIGA), the approved drug against Smallpox.

This lung infection study substantiates the results of the previously reported intradigital footpad infection study that: (i) NV-387 has comparable antiviral activity as tecovirimat, and
(ii) NV-387 plus tecovirimat has much stronger antiviral activity than either drug alone.

We have completed a lethality animal study wherein animals were infected with ectromelia virus into the lungs directly. In this study, we found that NV-387 alone treated animals survived 15 days, tecovirimat alone treated animals survived 16 days, and NV-387 plus tecovirimat treated animals survived 19 days, whereas vehicle-treated animals died in 8 days.

This lung-infection study emulates infection from aerosolized dispersion of the virus, as may be expected in a bioterrorism scenario.

Survival Lifespan of Lethally Infected Mice – Lung Infection with Ectromelia Virus

Previously, on November 14, 2023, we have reported that in a lethal intradigital footpad infection of mice with ectromelia virus, oral NV-387 treatment led to lifespan improvement comparable to oral tecovirimat treatment, with both treatments resulting in 14 days survival, whereas vehicle treated animals died in 8 days. Moreover, combined treatment with both NV-387 and tecovirimat resulted in a significantly improved survival of 17 days in this study.

Survival Lifespan of Lethally Infected Mice – Intradigital Footpad Infection with Ectromelia Virus

This intradigital footpad infection study emulates the skin-to-skin transfer of the virus as in sexual transmission, such as that in the case of current Clade 1 MPox virus epidemic in the DR Congo; Clade 1 MPox is more deadly than the Clade 2 MPox; the latter had caused a small pandemic recently with sexual mode of transmission (https://www.sciencefocus.com/news/monkey-pox-new-strain , May 5, 2024).

Tecovirimat is the drug approved for smallpox under “animal rule” and is stockpiled by the Biomedical Advanced Research and Development Authority (BARDA). It was mobilized from the stockpile during the recent MPox Clade 2 pandemic. BARDA is interested in development of additional poxvirus therapeutics as per a recent Broad-Agency Announcement (BAA). There is significant interest in the development of a smallpox therapeutic that works well by itself, as well as in combination with the known drug, tecovirimat. Tecovirimat has a low barrier of escape; a single mutation in one protein can enable the virus to escape this drug, adding to the significance of additional smallpox drug development.

Therefore we believe that NV-387 is a viable clinical candidate to be developed by itself for the treatment of poxvirus infections under the US FDA “Animal Rule”. In addition, we believe that the combination of NV-387 and tecovirimat could reduce the potential for escape resistant generation against tecovirimat, as is known with other drug combination studies against viruses.

A safe and effective antiviral drug that the virus would not escape by simple mutations or field evolution is the holy grail of antiviral drug development. We believe that the NanoViricides Platform technology meets this challenge.

‍

NEWS

MANAGEMENT

‍

Anil R. Diwan, PhDExecutive Chairman, President

Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.

Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.

He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.

Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)

interim Chief Financial Officer

Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.

Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.

NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.

‍

Randall W. Barton, PhD.Chief Scientific Officer – Consulting

Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.

Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.  

Jayant Tatake, PhD.

Vice President, R&D

Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.

Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

‍

Categories
Report

TGL

Treasure Global to Report Third Quarter Fiscal Year 2024 Results on May 14, 2024

8% of Malaysia has already bought into the concept with 2,680,000 registered ZCITY users in the country with a population of 34 million

TGL Recently Took Measures to DRASTICALLY Reduce the Size of the Float!!

READ THE COMPANY PRESENTATION HERE

___________________________

Hello Everyone,

We have a new profile that we want you to get on your radar for next week.

This is a company that just completed a 1:70 reverse split back in February.

This drastically reduces the float when a company does that.

We have covered a few companies recently that completed reverse splits and went on to show immense volatility due to the limited number of shares available.

There is no way to tell if this is exact but Finviz has the entire float at just over a Half Million Shares.

If true then that could explain why TGL has been on the move.

This one just touched 6 bucks on Friday and has closed green 3 of the last 4.

Two of those sessions it closed up double digits (12.5% & 17%).

Recently the company announced that it will report its financial results for the third quarter of fiscal year 2024, which ended on March 31, 2024, after market close on Tuesday, May 14, 2024. This could be a major catalyst this week for the company depending on what they report.

TGL has demonstrated consistent year over year profit growth from the company.

Recently revenues have been down and profits have been up because the company has been focusing on increasing growth in higher-margin revenue channels.

Gross profit for the second quarter of the 2024 fiscal year was approximately $0.35 million, a 48% improvement year-on-year, from approximately $0.23 million for the second quarter of the 2023 fiscal year. The increase in gross profit was primarily due to initiatives mentioned above that the Company is implementing to grow gross margins.

Treasure Global Inc (TGL) is a Malaysian e-commerce company whose mission is to “bring together the worlds of online e-commerce and offline physical retailers.”

Its proprietary app, ZCITY, is kind of like Google Pay meets Groupon, but operates in Malaysia.

ZCITY gives users a simplified e-payment solution while allowing them to earn rewards from cash rebates to exclusive discounts and vouchers.

From the merchant side, companies can send ZCITY users personalized deals based on purchase history, location, and preferences — all powered by artificial intelligence.

ZCITY even allows users to pay things such as utility bills, rent, or TV subscriptions, all while earning “Zcoins,” which can be redeemed for a variety of rewards.

Launched in Malaysia in July 2020, ZCITY has already achieved significant market penetration, with 2,680,000 registered users and 2,000 registered merchants/brands as of December 2023.

To put that in perspective, Malaysia’s population is 34 million, meaning 8 percent of them are registered users on ZCITY.

‍

TGL’s other main app is TAZTE, which is kind of like the Malaysian Yelp but with payment integration via ZCITY.

Merchants can set discounts, provide rewards, and offer loyalty programs all through the app. It also features inventory management and consumer behavior analysis.

‍

Recent Business Highlights

  • Over 2.68 million registered users as of December 31, 2023.
  • 53% of paid users transacted three or more times in the quarter ended December 31, 2023.
  • Quarterly active users for the quarter ended December 31, 2023 were 156,979.
  • Paid users down by 64% year-over-year.
  • A total of 0.58 million transactions were transacted by our registered users in the quarter ended December 31, 2023.
  • Signed a memorandum of understanding between ZCITY and Malaysia’s leading healthcare group, UCSI Hospital, to pioneer stem cell healthcare tourism for Indonesia, Hong Kong and China.
  • Signed an agreement for Treasure Global’s Abe Yus to supply its high-selling curry puffs to the world’s largest convenience store chain.
  • Announced major shareholder lock-up agreement.
  • Unveiled premium store, paving the way for an elevated ZCITY experience and substantial growth.
  • Announced closing of $4.0 million public offering.
  • Signed agreement to retire convertible debt notes.
  • Hosted historic artificial intelligence (“AI”) robot for TikTok Live Commerce in Malaysia.
  • Entered booming global gaming market, launching 10 mini games integrated with AI Game Creator in ZCITY’s 3D World.
  • Launched ZCITY Live Commerce solution on Meta Platforms.
  • Collaborated with AIO Synergy Solutions on development of data center for AI applications.

Revenue Streams:

  • E-vouchers — “Users can purchase ewallet reload vouchers, petrol vouchers, shopping vouchers with instant rebates”
  • Zmembership — “Offering bundles of discounted promo codes and attractive Zcoins to enhance consumption”
  • Zstore — “An ecommerce platform to earn more rewards while purchasing goods; referral program; lower prices with the Group Buy function”
  • Bill Payment — “Offering more than 15 billers enabling users to pay utility bills, loans, etc in 1 app”
  • TAZTE — “An end-to-end smart order system focused on SME Food & Beverage (F&B) Merchants”
  • Foodlink Global — “F&B franchisor revenue streams including start up fee and monthly licensing fees”
  • Others — “Miscellaneous income e.g. affiliate income, commissions and advertisement, etc”

Treasure Global’s ZCITY Secures US$2Million Marketing Contract through its AI Marketing Engine

Promoting Prestige Korean Beauty Products to Malaysia and Southeast Asia market

NEW YORK and KUALA LUMPUR, Malaysia, May 09, 2024 (GLOBE NEWSWIRE) — Treasure Global Inc (NASDAQ: TGL) (“Treasure Global” or the “Company”), an innovative technology solutions provider, is thrilled to announce that its subsidiary, ZCITY, has secured a groundbreaking US$2 million marketing contract. This contract, honored by Satria Dunia Sdn Bhd, aims to promote prestige Korean beauty products through ZCITY’s advanced artificial intelligence marketing engine (“AI Marketing Engine”).

This strategic move signifies a significant milestone for Treasure Global as ZCITY expands its presence and capabilities in the beauty industry. Leveraging ZCITY’s cutting-edge artificial intelligence technology, Treasure Global is poised to maximize brand visibility and drive sales growth for its clients’ Korean beauty products.

The Malaysian beauty market presents immense potential for revenue generation, with Korean beauty products gaining significant traction in recent years. According to market statistics, the revenue of the Korean beauty products market in Malaysia is projected to surge, with a compound annual growth rate (“CAGR”) of 9.54% from 2023 to 2032. In 2022 alone, the market revenue was valued at approximately US$313 million, underscoring the lucrative opportunities present in the region.¹

“This alliance underscores our commitment to revolutionizing the beauty industry through innovative marketing solutions. With ZCITY’s AI Marketing Engine, we are well-positioned to capitalize on the burgeoning demand for prestige Korean beauty products in Malaysia and beyond. This collaboration represents a strategic move to drive revenue growth and solidify our presence in the dynamic beauty market,” said Sam Teo, Chief Executive Officer of Treasure Global.

‍

NEWS

MAY 10, 2024 7:00PM EDT

Treasure Global Announces 2024 Annual General Meeting of Shareholders

MAY 09, 2024 8:00AM EDT

Treasure Global’s ZCITY Secures US$2Million Marketing Contract through its AI Marketing Engine

MAY 01, 2024 8:00AM EDT

Treasure Global to Report Third Quarter Fiscal Year 2024 Results on May 14, 2024

APR 11, 2024 8:30AM EDT

Treasure Global’s ZCITY is Anticipated to be Appointed Operator of Malaysia Pavilion, Tapping into Lucrative China Market

MAR 26, 2024 8:00AM EDT

Treasure Global Successfully Regains Compliance with Nasdaq Minimum Bid Price Requirement

MAR 08, 2024 8:00AM EST

Treasure Global’s AI-Powered ZCITY Premium Store Surpasses Expectations, Selling over 6,000 Bill Saver Bonanza Packs Within Four Months of Launch

FEB 23, 2024 11:00AM EST

Treasure Global Announces 1:70 Reverse Stock Split

FEB 22, 2024 8:00AM EST

Treasure Global and Silica-AI Forge Strategic Partnership to Revolutionize AI and IoT Landscape Across Southeast Asia

FEB 14, 2024 5:00PM EST

Treasure Global Reports Second Quarter Fiscal Year 2024 Results

FEB 05, 2024 8:30AM EST

Treasure Global CEO Demonstrates Confidence in Company’s Future Through Share Purchase

‍

MANAGEMENT TEAM

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY TGL AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

DFLI

Dragonfly Energy's leadership team posed witha Dragonfly IntelLigence product

2023 Net Sales were $64.4 million

As the RV industry is forecasted to climb back to June 2022 levels by Q4 2024, where annualized revenue of $104.4MM was achieved, the growth in OEM partnerships are expected to be strong catalyst in growth for Dragonfly Energy!

Dragonfly Energy Battle Born Batteries now come as factory installed standard equipment on all new OGV Luxury Coach units, a new division of Forest River Inc., a subsidiary of Berkshire Hathaway Company

READ THE FULL PRESENTATION HERE

________________________

Hello Everyone,

Dragonfly Energy Holdings Corp. (NASDAQ: DFLI) is at the forefront of the lithium boom as a domestic industrial leader in green energy storage and the maker of game-changing Battle Born Batteries®!

Through its renowned Battle Born Batteries® brand, Dragonfly Energy has established itself as a frontrunner in the lithium battery industry, with hundreds of thousands of reliable battery packs deployed in the field through top-tier OEMs and a diverse retail customer base.

Standing at the forefront of domestic lithium battery cell production, the company’s patented dry electrode manufacturing process can deliver chemistry-agnostic power solutions for various applications, including energy storage systems, electric vehicles, and consumer electronics.

Dragonfly Energy Holdings (NASDAQ: DFLI) has set out to develop cleaner and less wasteful processes to create lithium-ion batteries. Dragonfly produces batteries that solve today’s lead-acid problemand is creating next-generation nonflammable solid-state batteriesto address tomorrow’s energy storage needs.

The company’s cutting-edge technology enables widespread conversion to green, renewable energy.

Global demand for batteries is increasing, driven largely by the imperative to reduce climate change through electrification of mobility and the broader energy transition.

The global demand for lithium-ion batteries is poised for an unprecedented surge in the next decade. By 2030, the requirement is projected to skyrocket from about 700 GWh in 2022 to approximately 4.7 TWh!

Lithium-ion batteries power the lives of millions of people each day. From laptops and cell phones to hybrids and electric cars, this technology is growing in popularity due to its lightweight, high energy density, and ability to recharge.

Battery demand for EVs continues to rise. Automotive lithium-ion (Li-ion) battery demand increased by about 65% to 550 GWh in 2022, from about 330 GWh in 2021, primarily as a result of growth in electric passenger car sales, with new registrations increasing by 55% in 2022 relative to 2021.

The Outlook finds that under today’s policy settings, every other car sold globally is set to be electric by 2035. Meanwhile, if countries’ announced energy and climate pledges are met in full and on time, two in three cars sold will be electric by 2035!

With the future anticipated to be powered by lithium, a domestic battery supply chain has become a priority.

The U.S. has a lofty goal to reduce its reliance on foreign lithium supply and increase the nation’s energy self-sufficiency. The National Blueprint for Lithium Batteries 2021-2030, developed by the Federal Consortium for Advanced Batteries, outlines the country’s plans to bolster investments in the lithium supply chain, beginning with mining to processing and production.

China dominates the global supply chain for lithium-ion batteries prompting North America to scramble for more control over the “white oil.”

And despite short-term headwinds, there is a consensus in the mining and auto industries that long-term demand for lithium is expected to continue to outpace ALL OTHER METALS in the years ahead.

‍

                                   COMPANY HIGHLIGHTS

‍

RECENT HIGHLIGHTS

Announced expanded market share with inclusion as standard equipment by recreational vehicle (“RV”) giant, Forest River (link)

Announced the John Lennon Educational Tour Bus is now powered by Battle Born Batteries, moving the nonprofit mobile recording studio toward improved sustainability (link)

Announced partnership with Ameresco to boost renewable energy and power system applications (link)

Announced Coachmen RVs will include Battle Born Batteries as an optional upgrade on its Entourage Class C Motorhomes (link)

Announced entrance into heavy-duty trucking market, with new Battle Born All-Electric APU, enabling reduced fuel costs, increased uptime and payload, and lower harmful emissions (link)

Announced successful cathode electrode dry deposition, at scale, for American made lithium batteries (link)

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI): At the Forefront of Lithium-Ion Technology for Renewable Energy Storage.

Harnessing the power of the sun, utilizing the strength of the wind, and turning the movement of water into power—renewable energy is all around us. But what happens if the water dries up, when the sun sets, and when the wind dies down? We lose power. But what if we didn’t have to? What if we could ensure that we use every ounce of that energy, whether it’s intermittent or not? The solution is storage.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has been at the forefront of integrating lithium-ion technology to deliver environmentally impactful solutions for energy storage. Their batteries have powered RVs, marine vessels, industrial applications, and off-grid properties for years, and now is the time for a bigger, brighter future. As our world makes the shift, living off green energy is possible, no matter how intermittent that source is. Through manufacturing and advanced research and development, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) is putting Americans to work and developing technology for our future.

Powering life on the water, on the road, at home, or at work, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)is here to harness the unlimited potential of renewable energy. They’re increasing the adoption of energy sources, reducing emissions, and furthering the energy transition from being tied to the grid to being free and sustainable. As the industry leader in green energy storage, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)is powering lives with products that are safe, reliable, and powerful—products that are revolutionary.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) —solving intermittency today for smarter energy storage tomorrow, and developing a cleaner, brighter future for generations to come.

‍

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI): What’s Next in Grid-Level Storage & Harnessing Renewable Energy

The transition to renewable energy storage represents a pivotal and essential shift towards a brighter, more sustainable future. At the forefront of this transformation is Dragonfly Energy Holdings Corp. (Nasdaq: DFLI), a company that is revolutionizing how we store power and paving the way for innovative energy solutions.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s role extends far beyond that of a typical battery company. In fact, it is a trailblazer in the field of technology and innovation. The company’s primary focus is on developing and enhancing battery technology, including the creation of new battery packs, innovative battery cell manufacturing processes, and related products. Dragonfly Energy’s mission is to address and solve key challenges in energy and electricity production, both in the United States and around the world.

The critical challenge facing renewable energy is not cost, but rather intermittency—the fluctuating availability of sources like sunlight and wind. This is where Dragonfly Energy’s expertise in battery technology becomes vital. As a cutting-edge technology company, Dragonfly Energy is dedicated to developing energy storage solutions that allow renewable sources like wind and solar to effectively compete with traditional energy sources such as coal, oil, and gas. The company empowers individuals and communities to enjoy extended periods of independence from the grid—a capability that has become increasingly crucial.

With traditional lead acid batteries having remained relatively unchanged for 150 years, Dragonfly Energy, along with its consumer brand Battle Born Batteries, has introduced game-changing solutions. The company provides ideal replacements for conventional lead acid batteries, leading to a transformative shift in how recreational vehicles (RVs), marine vessels, and off-grid customers power their lifestyles.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s approach involves the assembly and marketing of battery packs to consumers and original equipment manufacturers (OEMs) for a range of applications. This is done through both the Battle Born Batteries and Dragonfly brands. In addition to batteries, Dragonfly Energy offers complete energy systems, including inverters, solar charge controllers, and solar panels. By offering these comprehensive solutions, the company gains valuable insights into the evolving energy industry, enabling it to drive conversations and innovations in larger-scale applications such as emergency backup power and industrial power.

For those at Dragonfly Energy with a scientific background, the opportunity to deploy and develop cutting-edge technology for solving real-world problems is a driving passion. The company is committed to making a positive and lasting impact on the world through its research and development efforts.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s pioneering work extends to the realm of solid-state battery technology—a field in which the company is introducing unprecedented innovations. While many other companies in the solid-state technology space are primarily focused on the electric vehicle market, Dragonfly Energy has chosen to concentrate on the energy storage market—an area with vast potential and unique challenges.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s solid-state battery technology is distinctive and groundbreaking. It addresses critical concerns, such as the flammability of liquid electrolytes, by using solid electrolytes that are inherently safe. The company’s solid-state batteries will be manufactured in the United States, offering cost-effective and non-flammable solutions that can be safely deployed in a wide range of settings, from individual buildings to entire communities.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) Brings You Battle Born Batteries: Powerful, Reliable Lithium-Ion Batteries

The growth of Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) can largely be attributed to the company’s ability to deliver a product that met the pressing needs of a wide range of consumers. In particular, Dragonfly Energy made its mark in the recreational vehicle (RV) industry by addressing the shortcomings of traditional lead acid batteries, which were widely disliked by RV owners.

By combining a high-quality product with a rapidly growing industry like the RV market, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) set itself on a trajectory of remarkable success.

What set Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) apart from its competitors was the company’s strategy of identifying a problem in the market and then developing a solution that was not only powerful but also safe and reliable. Through forming relationships with influential customers, industry-leading OEMs, and grassroots campaigns, Dragonfly Energy was able to raise awareness about the dangers and limitations of lead-acid batteries, thereby revolutionizing the industry.

Since 2018, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has sold over 175,000 of the most popular deep-cycle lithium-ion batteries on the market, leading to rapid growth of both the Dragonfly Energy and Battle Born Batteries brands. The company’s products have been well received, not only for their superior quality but also for the exceptional customer service and support provided by the company.

Dragonfly Energy’s Battle Born Batteries brand was an early mover in the transition from lead acid to lithium-ion batteries in the RV industry. These new batteries were non-toxic, lighter weight, longer-lasting, and safer than their lead-acid counterparts. As a result, they not only improved customer experiences but also enhanced and powered their lifestyles.

The company’s commitment to understanding its customers’ needs and designing products to meet those needs has been a driving factor in its success. Dragonfly Energy started small, selling just one or two batteries per day, but it now sells thousands per month. This growth has been fueled by the company’s unwavering dedication to its customers.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s impact extends beyond the RV industry. Customers from various verticals and markets have sought out the company’s products to power their lives and activities. The ability to provide solutions to an increasingly diverse range of applications is a testament to Dragonfly Energy’s expertise and innovation.

For years, the RV industry was limited by outdated and dangerous technology. However, Dragonfly Energy’s introduction of lithium-ion batteries has been a game-changer, offering customers the freedom to power their lives in new and exciting ways. The company’s unique position as a battery technology company, rather than just a battery importer, allows it to take customer feedback and turn it into meaningful product development.

Dragonfly Energy’s approach to the RV industry was carefully planned. The company sought to educate early adopters about the benefits of its technology and drive business back to dealerships while simultaneously educating OEMs. This dual branding strategy positioned Dragonfly Energy on both sides of the market, resulting in widespread success and full market penetration.

As the market leader in RV batteries, Dragonfly Energy has no intention of resting on its laurels. The company plans to continue expanding, automating, and advancing its technology. This includes capturing adjacent markets and becoming a leader in the lead acid battery replacement market, which represents an enormous opportunity.

Pawn Star’s Star Rick Harrison Stands Behind Born Batteries®!

Rick Harrison, star of Pawn Stars in Las Vegas, lives off the grid four to five months out of the year on his unique property outside Port Orford, Oregon.

The property is an off-gridder’s dream paradise that is nowhere near any power lines or the grid. He successfully powers his three houses, two garages, and a complete machine shop from his LiFePO4 Battle Born Battery Bank.

Harrison did his due diligence and called a tech specialist at Battle Born. He was able to discuss his system requirements in detail with an expert. With the tech specialists’ insightful knowledge, Rick was able to purchase a power system specific to his off-grid home needs. To Rick’s delight, the performance of Battle Born Batteries matched the promises made.

“They worked as they said they work! A fact that is rare for many companies!” Rick stated.

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) Revolutionizing the Energy Storage Market Through Innovative Lithium-Ion Technology and Strategic OEM Partnerships

Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) has built a reputation for trust and reliability with DIY enthusiasts, sailing enthusiasts, and on- and off-road adventurers. This track record in the aftermarket has opened the door to partnerships with leading original equipment manufacturers (OEMs) in the industry. Through strategic OEM partnerships, Dragonfly Energy and its Battle Born Batteries brand have made their products widely available to consumers across the country via dealerships and as factory-standard and installed equipment.

The Battle Born brand played a significant role in rejuvenating the industry by focusing on the aftermarket and introducing lithium-ion batteries to recreational vehicles (RVs). This move caught the attention of OEMs, who realized that customers wanted lithium-ion batteries installed directly from the factory. As the company’s customer base embraced the benefits of lithium-ion technology over traditional lead acid batteries, Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) attracted the attention of major OEMs.

One such OEM partnership was with Airstream, the iconic RV brand. Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s success with Airstream led to other notable partnerships, including Keystone RV and Tiffin Motorhomes, which contributed to the company’s growing footprint in the OEM market.

Innovation and industry leadership characterized Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s partnership with Keystone RV. Keystone RV became the first company to put batteries on the assembly line and ship RVs to dealerships with batteries already installed. This groundbreaking move, which utilized Dragonfly Energy batteries, challenged preconceived notions in the industry and positioned Keystone RV as a leader in innovation.

The collaboration with Keystone RV has grown substantially, with Dragonfly Energy now serving as Keystone RV’s exclusive lithium battery supplier. This partnership not only speaks to the quality of Dragonfly Energy’s products but also to the company’s ability to meet high demand.

While Dragonfly Energy Holdings Corp. (Nasdaq: DFLI)’s OEM business is crucial for credibility and growth, the company continues to pursue other verticals, including material handling, the rail market, and the marine market. In essence, any application where a lead acid deep cycle battery is used today presents an opportunity for Dragonfly Energy’s lithium-ion batteries.

The company’s success in cultivating strong OEM partnerships has not gone unnoticed. Thor Industries, the parent company of Keystone RV and Airstream, recognized Dragonfly Energy’s potential to change the industry and the course of the planet. As a result, Thor Industries made a $15 million investment in Dragonfly Energy, further solidifying the relationship and expressing confidence in the company’s future.

Velociti and Dragonfly Energy Deliver an Immediate Return on Investment with Lithium Power Systems

MARCH 4, 2024

Innovative Instant ROI program allows fleets to achieve substantial and immediate savings from the deployment of Battle Born All-Electric Auxiliary Power Unit (APU)NEW ORLEANS, March 04, 2024 (GLOBE NEWSWIRE) — Velociti Inc., a global provider of technology deployment, maintenance and integration solutions, and Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), maker of Battle Born Batteries® and an industry leader in energy storage, today announced at American Trucking Associations Technology Maintenance Council’s Annual Meeting & Transportation Technology Exhibition, a partnership to provide Dragonfly Energy customers with access to the Velociti Instant ROI (Return on Investment) and VeloCare programs.

Successfully used by fleets for a variety of technologies and solutions, the Instant ROI program allows fleets to advance the use of their savings to pay for the technology, installation, and support services for the life of the solution.

“We created our Instant ROI program many years ago to bridge the gap between the technology our fleet customers desired and their ability to implement it due to hurdles like upfront investment and integration challenges,” said Deryk Powell, president of Velociti. “We’re constantly researching cutting-edge technologies we believe will give our fleet customers a competitive edge in challenging economic and regulatory conditions. When a solution like Dragonfly Energy’s All-Electric APU emerges, we’re thrilled to encompass it within the Instant ROI program. We believe this unique solution holds significant potential for the industry.”

Dragonfly Energy offers lithium-ion power systems, including the Battle Born All-Electric APU for heavy-duty trucks to run hotel loads, and power liftgates and other equipment. The solutions are more efficient than traditional diesel-powered APUs and other lead acid-based battery systems, providing fuel cost savings, lower emissions, and quieter operation.

Velociti Tech Examines the Battle Born All-Electric APU

Velociti’s Instant ROI allows customers to be cash positive from day one of a technology investment by providing deferred billing during the installation portion of a deployment project, and extended payment terms on the entire hardware, software, installation and support solution. With the addition of VeloCare, Dragonfly Energy customers receive proactive system health monitoring and comprehensive support, including field repairs using Velociti’s nationwide team of highly trained and skilled technicians.

“With VeloCare and Instant ROI from Velociti we are able to offer our customers a way to realize savings faster and better protect their investment in our technology,” said Wade Seaburg, chief revenue officer at Dragonfly Energy. “The ease of working with a single provider for deployment and support needs means fleets will have a more streamlined and comprehensive approach to reduce their environmental impact and provide increased driver comfort that can lead to improved driver retention.”

For more information about Battle Born Batteries, visit online. For more information about Dragonfly Energy, visit DragonflyEnergy.com.

About Dragonfly Energy
Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) headquartered in Reno, Nevada, is a leading supplier of deep cycle lithium-ion batteries. Dragonfly Energy’s research and development initiatives are revolutionizing the energy storage industry through innovative technologies and manufacturing processes. Today, Dragonfly Energy’s non-toxic deep cycle lithium-ion batteries are displacing lead-acid batteries across a wide range of end-markets, including RVs, marine vessels, off-grid installations, and other storage applications. Dragonfly Energy is also focused on delivering an energy storage solution to enable a more sustainable and reliable smart grid through the future deployment of its proprietary and patented solid-state cell technology. To learn more, visit www.dragonflyenergy.com/investors.

About Velociti Inc.,
For nearly 30 years Velociti Inc. has custom designed, installed, maintained, and partnered with a wide spectrum of technologies that solve complex business problems on a large scale. Velociti’s expert team bridges the gap between technology providers and enterprise customers, including Fortune 500 companies, to solve the many challenges companies face in today’s ever-evolving connected world. Whether for transportation and logistics, on and off highway fleets, hospitality and restaurant, retail, rail, healthcare, warehouse and distribution, manufacturing or construction, Velociti provides practical solutions and services that enable customers to maximize the return on technology investments.

Dragonfly Energy Expands Market Share with RV Giant Forest River

FEBRUARY 20, 2024

The RV Manufacturer’s New OGV Luxury Coach Division to Include Dragonfly Energy Lithium Batteries Standard on All Units

  • Dragonfly Energy Battle Born Batteries now come as factory installed standard equipment on all new OGV Luxury Coach units.
  • OGV Luxury Coach is the third Forest River, Inc. brand to include Battle Born Batteries as standard or optional equipment for customers.
  • This is the latest partnership in an ever-growing list of RV brands to implement Dragonfly Energy lithium batteries as standard equipment.

RENO, Nev., Feb. 20, 2024 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), maker of Battle Born Batteries® and an industry leader in energy storage, announces a new partnership with OGV Luxury Coach, a new division of Forest River Inc., a subsidiary of Berkshire Hathaway Company (NYSE: BRK.B), to provide Battle Born lithium batteries as standard equipment on all OGV units. Dragonfly Energy is the exclusive lithium provider for OGV Luxury Coach, marking the latest in a growing list of recreational vehicle partnerships for which the Company is providing power solutions.

Managed by well-known RV pioneer Tim Gray, the OGV Luxury Coach brand includes custom built Mercedes Sprinter Class B vans, as well as custom Prevost Bus conversions. The high-end brand aims to build premium quality, custom luxury coaches by leaning on Gray’s expertise and Forest River’s industry leadership.“Dragonfly Energy isn’t just a battery manufacturer to us, they’re a partner in our commitment to our customers’ safety and peace of mind,” Tim Gray, GM at Forest River Inc., said. “For Forest River’s newest premium line of coaches, reliability is non-negotiable, and the Battle Born Batteries product consistently delivers – giving our customers the trusted, high quality, and reliable power they need for their increasing energy demands on the road.”Introduced to the retail public at the 2024 Florida RV Super Show, the new OGV Luxury Coaches use Battle Born Batteries to replace the need for generators, providing customers a quieter, more environmentally friendly and cost-effective power solution. Dragonfly Energy provides a complete power system, highlighted by a large 1080AH (13 kWh) system that includes four heated Battle Born GameChanger 3.0 batteries. Customers can experience extensive off grid power while taking no additional space from the interior of the van thanks to an innovative mounting design that places the power beneath the van itself. In addition, the Battle Born Batteries system integrates seamlessly with the Garmin display, giving customers the ability to monitor and control the power system from inside the cab.One of the world’s largest RV manufacturers, Forest River, Inc. produces market share leaders in virtually every type of motorized and towable recreational vehicle. With an estimated 40-50% of the RV industry market share, the company has more than 100 plants and over 12,000 employees.Already, Dragonfly Energy’s Battle Born Batteries are included in other Forest River brands, including as standard equipment on Forest River’s FR3 motor coaches, Palomino Pause and as optional equipment on the Coachmen RV Entourage Class C Motorhome. The inclusion of the OGV Luxury Coach brand is the latest addition on a growing list of major recreational vehicle brands and manufacturers who now include Dragonfly Energy’s products as standard equipment in various models.

‍About OGV Luxury Coach
OGV Luxury Coach, managed by Tim Gray – the pioneer of today’s popular custom Class B van category – builds custom Mercedes Sprinter Class B vans, and custom Prevost Bus conversions as part of Forest River, Inc.Founded in 1996 by Pete Liegl to help more people experience the joy of the outdoors, Forest River, Inc. evolved into the largest manufacturer of recreational vehicles, cargo trailers, pontoon boats, buses, vans, and commercial vehicles in North America. Its recreational portfolio includes market share leaders in towable and motorized RVs, cargo trailers, and pontoon boats. It is the country’s leading supplier of commercial vehicles, and the country’s leading manufacturer of buses and vans for both the private and public sectors. Headquartered in Elkhart, Indiana, Forest River employs 12,000+ employees in 100+ facilities in more than a half dozen states. With a commitment to excellence and a focus on customer satisfaction, Forest River is proud to be a Berkshire Hathaway company.

‍

NEWS

MAY 8, 2024

Dragonfly Energy Named Business of the Year at Nevada Business Awards

APRIL 30, 2024

Dragonfly Energy Partners with the National Forest Foundation to Plant Trees in Honor of Earth Day

APRIL 29, 2024

Dragonfly Energy to Report First Quarter 2024 Financial and Operational Results on May 14, 2024

APRIL 15, 2024

Dragonfly Energy Reports Fourth Quarter 2023 and Full Year Financial Results

APRIL 10, 2024

Dragonfly Energy’s Domestic Battery Manufacturing Validated for Cost Effectiveness and Sustainability

APRIL 9, 2024

Dragonfly Energy to Report Fourth Quarter and Year End 2023 Financial and Operational Results on April 15, 2024

MARCH 4, 2024

Velociti and Dragonfly Energy Deliver an Immediate Return on Investment with Lithium Power Systems

FEBRUARY 20, 2024

Dragonfly Energy Expands Market Share with RV Giant Forest River

JANUARY 30, 2024

Dragonfly Energy Drives the John Lennon Educational Tour Bus Toward Sustainability

‍

MANAGEMENT TEAM

Dr. Denis Phares

Dr. Denis Phares leads with a passion for making the planet more sustainable. As the President and Chief Executive Officer of Dragonfly Energy Corp., he focuses on developing revolutionary technologies that will change the way we store and harness renewable energy. As a visionary leader, Phares has helped grow Dragonfly Energy and its consumer brand, Battle Born Batteries, into one of the leading Li-Ion products on the market while also leading a world class R&D team in the advancement of groundbreaking technologies and manufacturing processes. After establishing himself as a tenured professor of Aerospace & Mechanical Engineering at the University of Southern California, Phares left academia to found Dragonfly Energy in 2012. With three decades of extensive experience in the fields of Energy, Nanotechnology, Fluid Mechanics, and Powder Processing, Phares has positioned himself as a leading expert in Green Energy Storage and has spent the last 15 years focused on advancing lithium-ion battery technology. He holds a number of patents, some of which are key in fundamental battery cell manufacturing. Phares received a B.S. in Physics from Villanova University, an M.S. and Ph.D. in Environmental Engineering Science from California Institute of Technology, and an MBA from the University of Nevada, Reno.

Wade Seaburg

As the Chief Revenue Officer, Wade Seaburg leads Dragonfly Energy’s sales, business development and revenue growth & diversification efforts. Wade’s career and long-term success in business progression and B2B sales originated from his education at Purdue University where he earned a B.S. in Industrial Engineering and then through Eaton Corporation (ETN) where Seaburg completed their distinguished Technical Sales Training Program. Following 12 years as a Senior Account Representative within the WESCO (WCC) Distribution Manufactured Structures Division, Wade began his 5-year career as Founder and President at Structure Sales, a company focused on representing industry-leading suppliers to OEMs in the RV and Marine markets. Working as both a lead and co-inventor, Wade acquired three patents with the company. Wade began contract work with Dragonfly Energy in 2018 prior to fully joining the company as a Director of Outside Sales and Business Development in 2021, and now serving as Chief Revenue Officer of the company. During his time with Dragonfly Energy, Seaburg has helped grow the company’s OEM business and relationships exponentially, including being instrumental in successfully getting the company recognized as a “Five Rivet Supplier” with the iconic brand – Airstream RV. His work and strong B2B relationships also propelled the growth of the partnership between Dragonfly Energy and Keystone RV—where the two companies transformed the way an entire industry looked at battery power for RVs. Wade continues to prove Dragonfly’s ability to successfully serve high-volume OEM in various markets. Seaburg’s diverse skillset has led him to continually gain clear understanding of needs across industries and then to reach productive resolutions for all parties involved, including valued customers and stakeholders. As a valued leader, Wade has built a talented and experienced team around him at Dragonfly Energy as he continues to develop integral business relationships and new opportunities.

Tyler Bourns

Chief Marketing Officer, Tyler Bourns, leads the creative charge at Dragonfly Energy. With over 15 years spent producing story-rich, award-winning content for global brands, Tyler has received much recognition throughout his career. Today, he draws on his deep reserves of hands-on knowledge to push the envelope of strategic marketing at Dragonfly Energy. Tyler’s segue into full-time marketing is preceded by outstanding work in content creation with a strong focus on powerful storytelling and authenticity. His experience in video production and marketing extends over 12 years with the ownership and operation of the successful and award-winning video production company Bourns Productions Inc. In 2018 he was awarded the AAF Reno Ad Person of the Year alongside the region’s most respected advertising leaders. A three-time Emmy Award Winner, he has produced and filmed thought-leading content for Panasonic, GE Energy and Terrasmart, among many others. Tyler is no stranger to an international audience; he went on to produce an extensive library of video and photo content for the legendary rock band Whitesnake. In addition, he produced, wrote and directed an internationally distributed feature film, “Desert Shadows,” starring Mitch Pillegi (X-Files, Sons of Anarchy) and produced several worldwide acclaimed short films, two of which screened at the prestigious Cannes Film Festival. His role as Director of Photography on many of these film projects has helped develop his bold and thorough eye for big ideas and strong narratives. Community service has always been important to Tyler. He served on the Under30CEO Board of Directors in Reno for two years, encouraging, collaborating and training young business leaders in the community. Tyler has also served on the Board of Directors for the Cordillera International Film Festival since its inception in 2018. This festival secured its status as a FilmFreeway Top 100 Film Festival, a rare achievement for a festival less than five years old at the time. For over 6 years, through his video production company, Bourns Productions, Tyler helped Dragonfly Energy’s Battle Born Batteries brand grow to be one of the most respected and popular Deep Cycle Lithium-ion products on the market today. In 2021, Tyler joined Dragonfly Energy full time. Drawing on his hard-earned wealth of on-the-ground insight in production, Tyler strives to apply the same narrative-driven approach to marketing that brought him both recognition and fulfillment in the world of content creation. Steered by a strategy of creative authenticity, he brings a dynamic, experience-informed leadership style to Dragonfly Energy.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY DFLI AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

GWAV

Greenwave Technology Solutions Generates More than $9 Million Revenue in Q4 2023

GWAV Achieved over $30M in revenues last year and is on track to generate record revenues this year

GWAV operates 13 metal recycling facilities in Virginia, North Carolina, and Cleveland, OH

Company has improved its balance sheet by $27 million over the past 90 days

Greenwave believes it is on track to generate record revenues with record volume of steel processed in 2024

_________________________

Hello Everyone,

We have been profiling some extremely active companies as of late.

Our profiles have seen some volatility and produced some opportunities to look at these companies that have taken some significant swings.

We have another one to look at that is no stranger to big double digit swings.

Pull up GWAV Immediately.

The Company’s recycling facilities collect, classify, and process raw scrap metal (ferrous and nonferrous) and implement several unique technologies to increase metal processing volumes and operating efficiencies, including a downstream recovery system and cloud-based ERP system.

TLB Auto Shredder

Steel is one of the world’s most recycled products with the ability to be re-melted and re-cast numerous times. Recycling steel provides key environmental benefits over virgin metals, including reduced energy use, lower CO2 emissions, lower waste, and conserving natural resources. Greenwave’s customers include large corporations, industrial manufacturers, retail customers, and government organizations.

U.S. Steel Turns Down $7.3Bn Offer From Cleveland-Cliffs, Explores Alternatives – Potential Upside For Greenwave Technology Solutions, Inc. (Nasdaq: GWAV)?

Major developments in the steel industry are reshaping the landscape for key players. U.S. Steel, a significant player in the industry, has recently declined a substantial $7.3Bn acquisition offer from Cleveland-Cliffs and is now contemplating competitive proposals from Esmark Inc.

To add to the intrigue, there are rumors of ArcelorMittal SA considering entering the bid for this major steel manufacturer.

Amid this potential industry consolidation, GWAV emerges as a proactive contender, gearing up for an aggressive expansion strategy to meet the escalating demands of leading U.S. steel mills.

GWAV: Paving the Way for Growth in Metal Recycling

GWAV holds a prominent position as an operator of metal recycling facilities across Ohio, Virginia and North Carolina. Their core operations involve the collection, categorization, and processing of raw scrap metal, primarily to supply major steel mills and foundries. What sets Greenwave apart is its relentless pursuit of expansion and infrastructure enhancement, positioning itself as a key player during a potentially transformative phase in the steel industry.

Record-Breaking Growth: Positive Cash Flows and Expansion Plans

The first half of last year saw Greenwave Technology Solutions, Inc. (Nasdaq: GWAV) achieve remarkable growth, marked by substantial in-vest-ments in infrastructure that have begun yielding impressive results. Notably, the company achieved a significant milestone by generating $1.23Mn in positive cash flows from operations during the six months ending on June 30, 2023—a record achievement for the company.

Investing Heavily in Infrastructure

GWAV’s strategy of heavy infrastructure investment over recent years is now showing substantial promise. A standout example is the installation of a new automotive shredder and downstream processing system at its Kelford, North Carolina facility. This innovative system focuses on recovering millimeter-minus metal pieces from the residue left in the shredder. This previously discarded residue, often referred to as “fluff,” holds substantial value, but effectively extracting it has proven challenging. The downstream processing system is designed to overcome this hurdle.

The downstream system officially commenced operations in July 2023, introducing a fresh revenue stream set to kickstart in Q3 2023. The company forecasts that this system will generate an average daily revenue of $38,000, boasting margins exceeding 80%. Furthermore, it is well on its way to achieving over $1Mn in monthly revenue by the year’s end.

Future Growth Anticipated

GWAV is accelerating its progress toward these goals with the impending launch of a second automotive shredder at its Carrollton facility. This addition will effectively double the metal recycler’s capacity to process ferrous metal. The decision to shred ferrous metal rather than selling it in its unshredded form positions the company to command higher prices, generating an estimated 33% increase in additional revenue compared to unshredded ferrous metal.

In April, GWAV expanded its footprint with the opening of a new facility in Cleveland. Even though it has not yet reached its full volume potential, this location is already generating approximately $100,000 per month in revenue. As operations further ramp up, particularly with the commencement of a shear baler this month, the Cleveland facility is poised to generate $250k or more per month in revenue by next year.

As U.S. Steel explores alternative pathways in a potentially consolidating steel industry, GWAV stands out as a company actively positioning itself to seize new growth opp’s and strengthen its foothold in the ever-evolving world of metal recycling.

Greenwave’s Scrap App

Greenwave recently announced that its wholly-owned subsidiary, Scrap App, launched new AI-powered features to optimize pricing and sales. In a recent press release, Greenwave stated that the company anticipates Scrap App’s planned national expansion, coupled with its AI strategy, will accelerate growth.

Greenwave Chairman and CEO Danny Meeks stated “We plan to expand Scrap App to multiple new markets across the United States in the coming weeks. As a technology platform, Scrap App has the ability to scale to new markets with minimal capital investment – we do not have to open a new facility, purchase additional equipment, or significantly expand overhead when we enter a new city. We believe Scrap App has the potential to generate significant, high-margin revenue and create value for Greenwave shareholders.”

Greenwave Technology Solutions Further Strengthens its Balance Sheet

APR 23, 2024 7:07AM EDT

Company has improved its balance sheet by $27 million over the past 90 days

Chairman and CEO has converted all $17.22 million of his debt into equity

Company bolsters balance sheet with $5.25 million capital infusion

CHESAPEAKE, Va., April 23, 2024 /PRNewswire/ — Greenwave Technology Solutions, Inc. (“Greenwave” or the “Company”) (Nasdaq: GWAV), a leading operator of metal recycling facilities in Virginia, North Carolina, and Ohio, announced today that on April 22, 2024, it further strengthened its balance sheet by approximately $12 million.

Greenwave Technology Solutions (PRNewsfoto/Greenwave Technology Solutions)

Greenwave Recent Highlights:

  • Improved balance sheet by approximately $27 million over the past 90 days
  • Chairman and CEO exchanged approximately $17 million of debt into equity
  • Intends to utilize additional cash flow to aggressively grow operations
  • Anticipates starting operations for its second shredder in May
  • Plans to expand its wholly-owned technology platform, ScrapApp.com, into new markets and continue AI development
  • Plans to enhance margins of its Downstream Processing System with implementation of new Copper Extraction Technology
  • Expects to regain full compliance with all Nasdaq listing standards by the end of May
  • Seeks to accelerate efforts in social media, digital marketing and data analytics
  • On track to generate record revenues with record volume of steel processed in 2024

Greenwave Technology Solutions Strengthens Balance Sheet by Approximately $14.87 Million

PUBLISHED

APR 1, 2024 9:55AM EDT

Company Believes it Has Regained Compliance with Nasdaq’s Shareholder Equity Requirement

CHESAPEAKE, Va., April 1, 2024 /PRNewswire/ — Greenwave Technology Solutions, Inc. (“Greenwave” or the “Company”) (Nasdaq: GWAV), a leading operator of metal recycling facilities in Virginia, North Carolina, and Ohio, today announced that during the first quarter of 2024, it received proceeds from warrant exercises of approximately $2.81 million, converted approximately $2.06 million of third party debt to equity, and exchanged $10 million of related-party debt into equity. As a result of the foregoing, the Company has increased its shareholder’s equity by approximately $14.87 million.

The Company believes it has regained compliance with the minimum $2.5 million stockholders’ equity requirement and satisfies the minimum $5 million equity requirement for initial listing on The Nasdaq Capital Market.

Further, the Company has secured waivers from its senior secured note holders of the quarterly-cash covenants until September 30, 2024, as well as monthly amortization payments until July 31, 2024. The Company expects to utilize the additional cashflows from restructuring its debt to grow its operations.

Greenwave believes it is on track to generate record revenues with record volume of steel processed in 2024. For more information, please see the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on April 1, 2024.

Greenwave Technology Solutions’ Second Shredder Currently Being Connected to Power Grid by Dominion Energy Ahead of Schedule

PUBLISHED

MAR 25, 2024 8:34AM EDT

The second shredder is expected to boost annual revenues by approximately $4.8 million, with significant increase to gross profit

Second shredder on track to be connected to power grid by March 29, 2024 and commence operations shortly thereafter, doubling Greenwave’s annual shredded ferrous output

Greenwave is now one of the largest independent operators of metal recycling facilities on the East Coast

CHESAPEAKE, Va., March 25, 2024 /PRNewswire/ — Greenwave Technology Solutions, Inc. (“Greenwave” or the “Company”) (Nasdaq: GWAV), a leading operator of metal recycling facilities in Virginia, North Carolina, and Ohio, today announced that Dominion Energy is currently in the process of connecting its second automotive shredder to the power grid which is expected to be completed by March 29, 2024. The Company’s second automotive shredder is expected to commence operations shortly thereafter and double Greenwave’s annual shredded ferrous output.

https://mma.prnewswire.com/playmedia/2370348/second_shredder_video.html

Greenwave’s existing automotive shredder – an American Pulverizer 60×85 – is the same make and model as its second one, providing the Company expertise in its operation and maintenance. By shredding the steel Greenwave currently sells unshredded, the Company anticipates that it will be able to generate approximately 25-30% more revenue with significant margins on that steel volume.

In October 2023, Sims Metal Management acquired Baltimore Scrap Corp., which operated 17 metal recycling facilities and four shredders, for consideration of $220 million(1). Similar to most industries, there has been a tremendous amount of consolidation in scrap metal companies during the past several years. Greenwaveis now one of the largest independent chains of scrap yards remaining on the East Coast, with significant market share in its key markets. Further, the Company believes there is significant value in its licenses, municipal and corporate contracts garnered over its 20-year operating history, robust infrastructure, and team of seasoned experts.

“Greenwave’s second shredder provides the infrastructure for us to expand our footprint of metal recycling facilities up from 13 currently – significantly growing Greenwave’s revenues, margins, and free cashflow,” stated Greenwave CEO Danny Meeks. “We believe the market is significantly undervaluing Greenwave and firmly believe that by continuing our hub-and-spoke strategy of shredder hubs with feeder yards, we will become an increasingly attractive acquisition target of the major scrap metal conglomerates.”

Greenwave is on track to grow it revenues and volume of steel processed from 2023 levels in 2024.

Greenwave Technology Solutions Generates More than $9 Million Revenue in Q4 2023

PUBLISHED

JAN 22, 2024 12:31PM EST

Company Grows Revenues More than 10% Over Q3 2023

Greenwave Expects to Significantly Grow Revenues in FY 2024

CHESAPEAKE, Va., Jan. 22, 2024 /PRNewswire/ — Greenwave Technology Solutions, Inc. (“Greenwave” or the “Company”) (Nasdaq: GWAV), a leading operator of metal recycling facilities in Virginia, North Carolina, and Ohio, today announced that it generated more than $9 million in revenue during the fourth quarter of 2023. The news comes on the heels of the Company commencing operations of a metal baler, wire stripper, and three sheers at its non-ferrous processing facility in Portsmouth, VA last week.

Greenwave is poised to accelerate its revenue growth in 2024, aided by the significant capital expenditures the Company has made over the past twenty-four months, some of which include additional processing equipment, a fleet of trucks to more efficiently transport materials for processing and sale, and technologies aimed at growing top line sales as well as creating operating efficiencies to enhance margins.

With more than 20 years of experience in the metal recycling industry, Empire’s leadership has grown the Company through nearly every economic climate and is committed to creating long-term shareholder value.

NEWS

‍

MANAGEMENT TEAM

Danny Meeks – Chairman & CEO

At 18 years old, with one truck, Danny Meeks started a hauling company which he quickly expanded by re-investing its profits. Within two years, Mr. Meeks had won contracts to provide hauling services for some the region’s largest projects, including the expansion of the Chesapeake-Bay Bridge Tunnel.

In 2000, Mr. Meeks started Meeks Disposal Corporation with 1 truck and 10 roll-off cans, which he quickly expanded to 100 trucks and 3,500 roll-off cans. After Hurricane Katrina hit, Meeks Disposal was awarded a $100 million federal subcontract for the clean-up of New Orleans, under which Mr. Meeks oversaw 1,500 trucks and 5,000 people. Mr. Meeks sold Meeks Disposal Corporation for $17 million in 2010.

In November 2012, Mr. Meeks was elected to Portsmouth City Council, where he served on the industrial, zoning, housing authority, economic development, and port & development boards. He was also a member of the budget committee, where he was instrumental in helping set the city’s $750 million annual budget that gave city employees raises without increasing taxes.

In 2002, Mr. Meeks started DWM Properties, LLC, through which he’s steadily built a portfolio of 106 properties valued at approximately $27 million.

In 2012, after Super Storm Sandy hit, Mr. Meeks started Select Recycling Waste Services, Inc., which was awarded a federal subcontract to provide cleanup services in New Jersey. In 2016, it started a trash division which expanded to 70 trucks and 4,700 front load and roll off containers. In 2020, Mr. Meeks sold the majority of SRWS’ assets for $27 million and in 2021, he sold the remaining assets for an additional $3 million.

In 2004, Mr. Meeks founded Empire Services, Inc. with 1 yard and over the past 17 years, he has expanded it to 11 yards and $25 million in annual revenue through both acquisitions and opening new locations from scratch.

Mr. Meeks is well-suited to serve on our Board due to his significant business and management experience and deep knowledge of growth and commercialization strategies. Mr. Meeks joined the Company’s Board to foster revenue-generating capabilities of the Company.

Chief Financial Officer

Mr. Isaac Dietrich – Isaac Dietrich founded Greenwave and previously held the following positions with the company: Chief Executive Officer (April 2013 – October 2017, December 2017 – September 2021); Chairman of the Board (April 2013 – October 2017, December 2018 – June 2021); Chief Financial Officer (April 2013 – May 2014, August 2017 – October 2017, March 2021 – November 2021); and a member of its Board of Directors (April 2013 – November 2021). Mr. Dietrich was a consultant to Greenwave from February 2022 to April 2023.During this time, Mr. Dietrich was instrumental in closing public and private offerings of equity instruments for proceeds of tens of millions of dollars, developing a shareholder base of more than 27,000 investors, and closing an acquisition that resulted in the company generating $33.9 million in revenue in fiscal year 2022.From September 2022 to present, Mr. Dietrich has served as the Director of Finance of Thumzup Media Corporation. Since February 2023, Mr. Dietrich has served on Alpha Energy, Inc.’s Board of Directors and as Chairman of its Audit Committee.

Independent Directors

Mr. Henry Sicignano – Mr. Sicignano currently serves as the President of Charlie’s Holdings, Inc. (OTC: CHUC), a publicly traded consumer goods company with sales extending to more than 90 countries, a role which he has held since April 2021. Prior to this role, from March 2015 through July 2019, he served as Chief Executive Officer of 22nd Century Group, Inc. (Nasdaq: XXII), a publicly listed plant biotechnology company. Additionally, Mr. Sicignano has served as director of Kartoon Studios, Inc. (NYSE: TOON) since May 2023 and served as General Manager at NOCO Energy Corp, as well as Vice President at Kittinger Furniture Company, Inc. He also served on the board of directors of Anandia Laboratories, Inc., which was acquired in 2018. Mr. Sicignano holds a B.A. degree from Harvard College and an M.B.A. degree from Harvard University.  Mr. Sicignano serves chairman of the Audit Committee and as a member of the Compensation and Nomination and Corporate Governance Committees.

Mrs. Cheryl Lanthorn – Mrs. Lanthorn began her career as a Personal Administrator at Welton, Duke & Hawks before rising to an Accounting Administrator due to her work-ethic, extensive accounting knowledge, and attention to detail. For the next 14 years, Mrs. Lanthorn was a Software Trainer and Content Developer for Applied Systems, Inc., where she created webinars and instructional documentation to teach employees how to best utilize TAM, Vision, Epic, and other scalable software programs. From December 2015 to July 2022, Mrs. Lanthorn served as an Account Executive at Brown & Brown Insurance, where she managed one of the company’s largest books of business, managed employees and their books, trained new employees, and performed various other administrative duties. Since August 2022, Mrs. Lanthorn has been a Senior Account Manager at Marsh Mclennan Agency, LLC, where she manages large corporate accounts.  Mrs. Lanthorn serves on as Chairwoman of the Compensation and Nomination and Corporate Governance Committees and as a member of the Audit Committee.

Mr. John Wood – Since 1998, Mr. Wood has served as a licensed real estate agent in Virginia. Since 2010, He has served as the Principal Broker of John E. Wood Realty, Inc., based in Chesapeake, Virginia, where through his extensive relationships with business and community leaders, he has become one of the region’s most active real Residential, Commercial and Property Management Brokers. He is also the Virginia Principal Broker for two other companies, which rank in the top 10 in the nation.  In July 2018, he launched American Contracting Services, LLC, which has successfully completed hundreds of Commercial and Residential construction projects.  Mr. Wood serves on the Company’s Audit, Compensation, and Nomination and Corporate Governance Committees.

Mr. Jason Adelman – Mr. Adelman is the Founder and Managing Member of Burnham Hill Capital Group, LLC, a privately held financial advisory firm, and serves as Managing Member of Cipher Capital Partners LLC, a private investment fund. Mr. Adelman also serves as a member of the board of directors of Trio-Tech International (Nasdaq: TRT) and Oblong, Inc. (Nasdaq: OBLG). Prior to founding Burnham Hill Capital Group, LLC in 2003, Mr. Adelman served as Managing Director of Investment Banking at H.C. Wainwright and Co., Inc. Mr. Adelman graduated from the University of Pennsylvania with a B.A. in Economics, cum laude, and from Cornell Law School with a J.D. degree.  Mr. Adelman serves on the Company’s Compensation, and Nomination and Corporate Governance Committees.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY GWAV AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

Knightscope

KSCP has inked dozens of major deals across the country – including 18 new contracts in April 2024 valued at over $1 million in addition to a 128% increase in revenue for 2023‍

KSCP integrates autonomy, robotics, AI, and EV technology, including Automated Gunshot Detection

They jut completed a pilot contract with the New York Police Department (NYPD) for a K5 robot to patrol a Manhattan subway station with the support of the Metropolitan Transportation Authority (MTA)

‍Hello Everyone,

Experts have warned us that AI is coming for our jobs for years…

But most people assumed it was a problem for the future generation and pushed the idea aside.

That is, until generative AI titan ChatGPT blasted onto the world stage and upended the way we perceive the future.

ChatGPT gave the world an acute awareness that AI dominance isn’t a future fantasy — it’s a present reality.

But ChatGPT is just the tip of the AI iceberg.

AI-powered robots are also taking the world by storm.

Billions of dollars are being spent to develop new groundbreaking robots across limitless industries ranging from healthcare to IT.

‍

Robotics Investments by Month

‍

Robot startup Figure AI – valued at $2.6 billion – has raised $675 million from investors like Jeff Bezos, Microsoft and NVIDIA.

Honda and Hyundai Motor’s Boston Dynamics are developing humanoid robots.

Tesla is looking to launch its Optimus robots by the end of 2025.

It’s not just car manufacturing.

Robots are also proving to be indispensable as public servants.

And there’s one AI security robotics stock that’s leading the global security robots market, which hit $32 billion in 2021 and it’s expected to grow at an impressive CAGR of 17.65% to reach nearly $120 billion by 2030.

This company could potentially be the most undervalued stock on the NASDAQ, trading at under 50 cents with a market cap of $47 million.

Knightscope, Inc. (NASDAQ:KSCP), a cutting-edge security technology company located in the heart of Silicon Valley.

The company manufactures ASRs (Made in America) equipped with state-of-the-art technology capable of deterring, detecting, and reporting crime.

When you look at the numbers, it becomes glaringly clear how important these robots are to public safety in the US.

Right now, there are over 331 million Americans. Yet, there are only 660,288 full-time law enforcement officers and just over a million security guards—roughly one protector for every 200 people.

In 2022, there were over a million violent crimes reported across the US.  

But, only about 41.5% of violent crimes are reported, so it’s much higher than FBI stats show.

One protector for 200 people simply isn’t enough.

That’s why Knightscope, Inc. (NASDAQ:KSCP) has leveraged four key technologies (autonomy, robotics, artificial intelligence, and EV technology) to better equip both domestic law enforcement and private businesses.

With high definition 360 degree live streaming and recorded video, thermal cameras and a public address speaker, ASRs provide additional eyes, ears and a voice to law enforcement – covering more ground and keeping the peace during all hours.

According to InvestorPlace, Knightscope could be a surprise hit among must-own AI stocks.

‍Knightscope has been given the green light by the US Government, being awarded its Authority to Operate. This authorization from the Federal Risk and Authorization Management Program (FedRAMP) is a massive win that makes this company’s cutting-edge technology available to federal agencies.

But that isn’t the only exciting news this company has shared in recent months.

‍Knightscope (NASDAQ:KSCP) has inked dozens of major deals across the country – including 18 new contracts in April 2024 valued at over $1 million – this is in addition to a 128% increase in revenue for 2023.

It caught the attention of investment banking and equity research firm Ascendiant Capital Markets analyst Edward Woo, who highlighted the company’s Q3 wins as a sign of what’s to come in 2024 in a recent research report.

Some notable deals Knightscope include a $1.2 million inventory replenishment order for its K1 Call Boxes, and a $1.25 million contract with Rutgers, The State University of New Jersey, for a whopping 145 devices.

‍

Knightscope (NASDAQ:KSCP) also completed a pilot contract with the New York Police Department (NYPD) for a K5 robot to patrol a Manhattan subway station with the support of the Metropolitan Transportation Authority (MTA).

According to the New York Times and a New York City spokesperson, it is on track to be deployed at another location.

Some of the other big-name clients utilizing Knightscope’s (NASDAQ:KSCP) technology include:

  • Port Authority New York New Jersey
  • Penn Entertainment
  • University of Tennessee
  • New York City Fire Department (FDNY)
  • San Bernardino County Transportation Commission (SBCTC)
  • San Luis Obispo Council of Governments (SLOCOG)
  • Orange County Transportation Authority (OCTA)
  • Ventura County Transportation Commission (VCTC).

Knightscope’s Florida-based reseller Transportation Solutions & Lighting (TS&L) also purchased 40 K1 Blue Light Towers to support its growing emergency communications business.

If that’s not enough, Knightscope (NASDAQ:KSCP) just began sales of its Automated Gunshot Detection (AGD) technology to cut the response time to dangerous situations down to two seconds!

Let’s take a look at some of the reasons this company is a force to be reckoned with in the public safety arena.

7 Reasons to Pay Close Attention to Knightscope (NASDAQ:KSCP)

  1. Innovation Leader: Knightscope (NASDAQ:KSCP) is a first mover security technology firm manufacturing Autonomous Security Robots (ASRs) equipped with advanced technology that can deter, detect, and report crimes.
  2. Advanced Technology Integration: Knightscope (NASDAQ:KSCP) uses four key technologies – autonomy, robotics, artificial intelligence, and EV technology to develop its unique and efficient security solutions. Recently launched real-time, Automated Gunshot Detection (AGD) and the Knightscope Emergency Management System (KEMS).
  3. Cost-Effective Solution: Knightscope‘s Machine-as-a-Service (MaaS) business model provides a cost-effective alternative to traditional security. Their services cost between $0.75 to $9.00 per hour. In comparison, an unarmed guard makes $15 to $35 per hour and an off-duty armed law enforcement officer can be well over $85 per hour.
  4. Ongoing Revenue Growth:Knightscope (NASDAQ:KSCP) announced a 128% increase in revenue year-over-year, generating an estimated $12.8 million in 2023. Yet, the company is trading at less than 50 cents with a market cap of $47 million (and ⅓ of the invested capital) – making it easily one of the most undervalued stocks on the NASDAQ.
  5. Successful Client Acquisition and Recurring Revenue Stream: Knightscope (NASDAQ:KSCP) just signed another 18 contracts over $1 million, adding to its growing roster of major clients across the US.
  6. Strong Growth Prospects: The ASR market is expected to grow significantly, reaching $116.44 billion by 2030.  Knightscope (NASDAQ:KSCP) also has a clear roadmap to profitability, targeting Q4 2024.

‍Relentless, Experienced Leadership Team: Management team holds over 10 million shares of the company’s outstanding shares.  Knightscope’sCo-founder & CEO, Chairman William Santana Li holds 7 million shares. He was the youngest senior executive at Ford Motor Company out of 430,000 employees at the time and later became COO at Ford subsidiary GreenLeaf, the world’s second-largest automotive recycler.

AI-Powered Autonomous Security Robots for Persistent Surveillance and Threat Detection

Knightscope (NASDAQ:KSCP) sets itself apart by employing cutting-edge technology in a unique approach towards combating violent crime in the US and beyond

Knightscope (NASDAQ:KSCP) is the only company that’s publicly traded and makes fully autonomous security robots (ASRs) for both indoors and outdoors at scale, but let’s compare them to other data-driven solution developers in the security space who are combating violent crimes in the US and beyond.

Knightscope’s comparables include companies like Axon Enterprise, which makes Tasers, body cameras, and VR training for officers.

Wrap Technologies makes a device called BolaWrap that police can use to restrain people from a distance.  

SoundThinking (formerly ShotSpotter) makes systems that can detect gunshots, high-tech security cameras, and a search engine for law enforcement— Knightscope has also recently added its own real-time, Automated Gunshot Detection (AGD) to its portfolio.

‍

Knightscope’s Unique Service Model and New Tech

Knightscope, Inc.’s (NASDAQ:KSCP) business model is called Machine-as-a-Service (MaaS), and it’s already generating significant revenue.

Think about it this way: a police officer’s salary can be between $57,000 and $67,000 and with all the extra costs, it can go up to $149,000. Knightscope’s service costs between $0.75 to $9.00 per hour. This includes everything from setting up the robot to storing the data it collects.

For example, a single K5 Autonomous Security Robot (ASR) can make $255,000 of revenue over a 5-year period and is either paid up front by the client or financed by a funding partner Total cash outflows over the period is ($84,530) yielding a margin of $170,470 or 67% as the long-term target!

Knightscope’s ASRs are not only cheaper to run, but they’re also reliable. Look at how they compare to the average security guard:

Plus, they’ve already helped solve crimes, like catching a hit-and-run suspect and identifying a gunman.

New Gunshot Detection Tech and Emergency Management System Platform

Knightscope (NASDAQ:KSCP) recently created a lot of buzz in the industry with the addition of real-time, Automated Gunshot Detection (AGD). This system can help police and security respond faster to threats. It’s a response to requests from schools, corporations, airports, hotels, and cities.

The benefits of gunshot detection include:

  • Helping to stop active-shooter events and save lives
  • Reducing false alarms
  • Working with other security solutions to protect people

The system can work on its own or with Knightscope’s K5 Outdoor and K3 Indoor ASRs as well as K1 Blue Light Towers.. It can also use solar power or light pole kits for more flexible installation.

The system can locate shots indoors and outdoors and sends notifications in less than two seconds. Knightscope believes that a focused, real-time system is more effective than a city-wide approach.

The market for gunshot detection systems is expected to reach $646 million by 2031 in North America.

Knightscope (NASDAQ:KSCP) also announced the launch of its innovative Knightscope Emergency Management System (KEMS).

Because the company operates a wide-reaching network of more than 7,000 devices across the US, including K1 Blue Light Towers, E-Phones, and Call Boxes, the introduction of the KEMS platform will boost these devices’ capabilities by allowing real-time monitoring, instant error detection, and system performance reporting.

It’s an exciting leap forward, made even more significant by Knightscope‘s (NASDAQ:KSCP) integration of AI throughout its product range.

The company’s continued rollout of the KEMS platform throughout 2023 promises a dynamic shift in public safety infrastructure, making the nation’s security more efficient and smarter than ever.

But that’s just the beginning of what this company has in mind.

Knightscope (NASDAQ:KSCP) plans to partner with award-winning, industry-leading drone solutions and systems developer Draganfly (NASDAQ:DPRO) (CSE:DPRO) to fully integrate Draganfly’s drone technology with its ASR tech to form a unified autonomous product.

NEWS

‍

‍

‍

MANAGEMENT TEAM

William Santana Li, Chairman and CEO

‍

William Santana Li

William (“Bill”) Santana Li has served as our Chairman and Chief Executive Officer (“CEO”) since April 2013. Mr. Li is an American entrepreneur with over 30 years of experience from working in the global automotive sector and founding and leading a number of startups. From 1990 to 1999, Mr. Li held multiple business and technical positions at Ford Motor Company across four continents.

His positions at Ford ranged from component, systems, and vehicle engineering with the Visteon, Mazda, and Lincoln brands; to business and product strategy on the United States youth market, India, and the emerging markets in Asia-Pacific and South America; as well as the financial turnaround of Ford of Europe. In addition, he was on the “Amazon” team, which established an all-new modular plant in Brazil. Subsequently, he served as Director of Mergers & Acquisitions.

After internally securing $250 million in financing, Mr. Li founded and served as COO of GreenLeaf LLC, a Ford Motor Company subsidiary that became the world’s second largest automotive recycler. Under his leadership, GreenLeaf grew to more than 600 employees, 20 locations worldwide, and annual sales of approximately $150 million. At the age of 28, Bill was the youngest senior executive at Ford Motor Company worldwide.

After successfully establishing GreenLeaf, Mr. Li was recruited by SoftBank Venture Capital to establish and serve as the President and CEO of the Model E Corporation, a newly established automobile manufacturer that focused on the “Subscribe and Drive” model in California. Mr. Li also founded Carbon Motors Corporation in 2003, and as its Chairman and CEO until February 2013, focused it on developing the world’s first purpose-built law enforcement patrol vehicle.

Mr. Li earned a BSEE from Carnegie Mellon University and an MBA from the University of Detroit Mercy.

‍Apoorv S Dwivedi, EVP and Chief Financial Officer

With extensive finance and corporate strategy experience, Dwivedi most recently served as the Chief Financial Officer of Nxu, Inc. (NXU). He joined the company in 2022 and helped to take it public on Nasdaq in the same year. He then led the company’s strategy around capital markets, investor relations, finance operations and corporate growth. Prior to his CFO role at Nxu, Dwivedi served as Director of Finance for Cox Automotive from 2019 to 2022 where he successfully ran the Manheim Logistics business. From 2018 to 2019, he was the Director of Presales at the SaaS company Workiva, and from 2010 to 2017 Dwivedi served in several corporate finance roles of increasing responsibility at the General Electric Company across both the GE Capital and GE Industrial businesses. Dwivedi began his career at ABN-AMRO, N.A. and was instrumental in building one of the first data analytics teams at Sears Holdings Company. Dwivedi earned his Bachelors in Finance from Loyola University – Chicago and his MBA from Yale School of Management.

Stacy D Stephens, EVP and Chief Client Officer

‍

Stacy D Stephens

Stacy Stephens is our Chief Client Officer and co-founded the Company in April of 2013. Previously, he co-founded Carbon Motors Corporation with Mr. Li, where he led marketing operations, sales, product management, partnership marketing and Client service. At Carbon Motors, Mr. Stephens established the “Carbon Council,” a Client interface and users group consisting of over 3,000 law enforcement professionals across all 50 states and actively serving over 2,200 law enforcement agencies.

Prior to co-founding Carbon Motors Corporation, Mr. Stephens served as a police officer for the Coppell (Texas) Police Department from 2000 to 2002. In recognition of his accomplishments, Mr. Stephens was named one of Government Technology magazine’s “Top 25 Doers, Dreamers & Drivers” in 2011.

Mr. Stephens studied aerospace engineering at the University of Texas in Arlington. He subsequently earned a degree in criminal justice and graduated as valedictorian from Tarrant County College in Fort Worth, Texas. He is a member of the International Association of Chiefs of Police (“IACP”) and also sits on the IACP Division of State Associations of Chiefs of Police SafeShield Project, which seeks to critically examine existing and developing technologies for the purpose of preventing and minimizing officer injuries and fatalities.

Mercedes Soria, EVP and Chief Intelligence Officer

‍

Mercedes Soria

Mercedes Soria is our Chief Intelligence Officer and has been with Knightscope since April 2013. Ms. Soria is a technology professional with over 15 years of experience in systems development, life cycle management, project leadership, software architecture and web applications development.

Ms. Soria led IT strategy development at Carbon Motors Corporation from 2011 until 2013. From 2002 to 2010, Ms. Soria was Channel Manager and Software Development Manager for internal operations at Deloitte & Touche LLP, where her team deployed software that was used daily across the firm’s thousands of employees. From 1998 to 2002, Ms. Soria worked as a software developer at Gibson Musical Instruments leading the effort to establish its online presence.

Ms. Soria obtained Bachelor and Master’s degrees in Computer Science from Middle Tennessee State University with honors, as well as an Executive MBA from Emory University. She is also a certified Six Sigma green belt professional and a member of the Society of Hispanic Professional Engineers.

Aaron J Lehnhardt, EVP and Chief Design Officer

‍

Aaron J Lehnhardt

Aaron Lehnhardt has served as our Chief Design Officer since November 2015. Previously, from the Company’s inception in April 2013 until November 2015, Mr. Lehnhardt served as Chief Designer of the Company. From 2002 to April 2013, Mr. Lehnhardt was the co-owner of Lehnhardt Creative LLC where he worked on advanced propulsion vehicle design, personal electronics, product design, video game design, and concept development work.

From 2004 to 2011, Mr. Lehnhardt was Chief Designer at California Motors (“Calmotors”), where he led the design for various concepts for HyRider hybrid vehicles, the Calmotors 1000 horsepower hybrid super car, Terra Cruzer super off-road vehicle, multiple vehicles for the U.S. Military, and various other hybrid and electric vehicles. He was also the lead designer and partner of Ride Vehicles LLC, a sister company to Calmotors, which worked on a 3-wheeled, standup personal mobility vehicle.

Jason M Gonzalez, SVP Client Development

‍

Jason M Gonzalez

Jason Gonzalez is SVP Client Development and has been with Knightscope since June 2018.  He is a security professional with over 20 years of experience, delivering solutions to the private and government sectors. He has extensive sales experience in both security technology and security services.

Mr. Gonzalez began his security career with Tyco Integrated Security in 1997, selling technology solutions across a broad range of commercial industries. His success there paved the way to join Honeywell’s Security and Fire division, where he drove sales through their reseller program in the Western U.S. He then transitioned to the security services side of the industry, leading him to join G4S Secure Solutions in 2006, a global service provider of security personnel and management. As the Regional Director of Business Development for the Western U.S., he was directly responsible for local and national account sales, including hiring, training and managing a sales team.

After nine years, and over $70M in revenue generated, Mr. Gonzalez moved on to a Regional Vice President role with Whelan Security, managing sales and complex security operations across five Western U.S. states with full P&L responsibility.

Throughout his career, Mr. Gonzalez has demonstrated his ability to develop strategic partnerships and drive high growth through optimizing sales channels, organizational productivity, and team building.

Ronald J Gallegos, SVP Client Experience

‍

Ronald J Gallegos,

Ronald Gallegos is SVP Client Experience and has been with Knightscope since 2016. Mr. Gallegos has over 21 years of experience working with the C-level in global physical security. He has served as a trusted advisor, providing solutions to global Fortune 1000 corporations, large public safety organizations and critical infrastructure entities. His background ranges from leadership in physical security human resources, systems integrations, global situational awareness & location-based social media Software-as-a-Service (SaaS) and autonomous robotics and artificial intelligence.

Mr. Gallegos started with the Northern California Regional team for AlliedBarton (AlliedUniversal) the largest US Security Services company, where he was promoted to Regional Manager for the San Francisco Bay Area. He later joined Securitas, one of the largest security contractors in the world, and was based in the Silicon Valley as a trusted advisor, initiating and project managing many Fortune 1000 implementations. He later excelled as a Regional Manager at G4S (Group 4 Securicor), the world’s largest security organization.

Prior to Knightscope, Mr. Gallegos served as Director of Enterprise Accounts at Geofeedia, where he managed a team and executed all aspects of enterprise software implementations for global physical security teams. He also helped launch the corporate security practice as well as acquired and managed relationships with more than 60 Fortune 500 strategic accounts.

Mr. Gallegos holds a BSBA and MBA from San Francisco State University. He has also served several years as a Board Member for the American Society for Industrial Security (ASIS) San Francisco Bay Area Chapter.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY KSCP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.